Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,507501,distribution,The distribution and the elimination phase half-lives averaged 2.9 and 42 minutes.,Pharmacokinetics of ketamine in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/507501/),min,2.9,469,DB01221,Ketamine
,507501,elimination phase half-lives,The distribution and the elimination phase half-lives averaged 2.9 and 42 minutes.,Pharmacokinetics of ketamine in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/507501/),min,42,470,DB01221,Ketamine
,507501,volume of the central compartment,The volume of the central compartment averaged 212 ml/kg of body weight and the volume of the peripheral compartment was approximately threefold larger.,Pharmacokinetics of ketamine in the horse. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/507501/),[ml] / [kg],212,471,DB01221,Ketamine
,507501,total body clearance,The total body clearance of ketamine averaged 26.6 ml/minute/kg.,Pharmacokinetics of ketamine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/507501/),[ml] / [kg·min],26.6,472,DB01221,Ketamine
,507501,Plasma protein binding,Plasma protein binding of ketamine averaged 50% over the concentration limits of 0.3 to 20 microgram/ml.,Pharmacokinetics of ketamine in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/507501/),%,50,473,DB01221,Ketamine
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],496,8051,DB01221,Ketamine
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],2104,8052,DB01221,Ketamine
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],632,8053,DB01221,Ketamine
,8881626,bioavailability,Calculated bioavailability was 0.50 in groups IN3 and IN9 and 0.25 in group IR9.,"Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),,0.50,8054,DB01221,Ketamine
,8881626,bioavailability,Calculated bioavailability was 0.50 in groups IN3 and IN9 and 0.25 in group IR9.,"Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),,0.25,8055,DB01221,Ketamine
,29030928,clearance,"The typical parameter estimates for clearance and central and peripheral volumes of distribution were: CLS-KETAMINE =112 L/h/70 kg, V1S-KETAMINE =7.7 L/70 kg, V2S-KETAMINE =545L/70 kg, QS-kETAMINE =196 L/h/70 kg, and CLS-NORKETAMINE =53 L/h/70 kg.",Pharmacokinetics of S-ketamine during prolonged sedation at the pediatric intensive care unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29030928/),[l] / [70·h·kg],112,9770,DB01221,Ketamine
,29030928,V1,"The typical parameter estimates for clearance and central and peripheral volumes of distribution were: CLS-KETAMINE =112 L/h/70 kg, V1S-KETAMINE =7.7 L/70 kg, V2S-KETAMINE =545L/70 kg, QS-kETAMINE =196 L/h/70 kg, and CLS-NORKETAMINE =53 L/h/70 kg.",Pharmacokinetics of S-ketamine during prolonged sedation at the pediatric intensive care unit. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29030928/),[l] / [70·kg],7.7,9771,DB01221,Ketamine
,29030928,V2S,"The typical parameter estimates for clearance and central and peripheral volumes of distribution were: CLS-KETAMINE =112 L/h/70 kg, V1S-KETAMINE =7.7 L/70 kg, V2S-KETAMINE =545L/70 kg, QS-kETAMINE =196 L/h/70 kg, and CLS-NORKETAMINE =53 L/h/70 kg.",Pharmacokinetics of S-ketamine during prolonged sedation at the pediatric intensive care unit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29030928/),[l] / [70·kg],545,9772,DB01221,Ketamine
,28759464,rate constant,"The inhalation data were best described by adding two absorption pathways, an immediate and a slower pathway, with rate constant 0.05 ± 0.01 min (median ± SE of the estimate).",Pharmacokinetics and Bioavailability of Inhaled Esketamine in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759464/),min,0.05,10945,DB01221,Ketamine
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,91-93,12804,DB01221,Ketamine
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,89-93,12805,DB01221,Ketamine
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,90-92,12806,DB01221,Ketamine
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],2.0,12807,DB01221,Ketamine
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),μg,3.9,12808,DB01221,Ketamine
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],3.2,12809,DB01221,Ketamine
,32065415,Elimination half-life,Elimination half-life was prolonged (7-9 hours) compared with published data from immediate-release oral formulations.,"Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32065415/),h,7-9,14712,DB01221,Ketamine
,526385,stable plasma concentration,This dose gave a stable plasma concentration of ketamine of 9.3 +/- 0.8 mumol litre-1.,Ketamine infusions: pharmacokinetics and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526385/),[μM] / [l],9.3,15764,DB01221,Ketamine
,526385,Plasma half-life,Plasma half-life of ketamine was 79 +/- 8 min.,Ketamine infusions: pharmacokinetics and clinical effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526385/),min,79,15765,DB01221,Ketamine
,526385,Maximum concentration,Maximum concentration of nor-ketamine was 4.7 +/- 2.4 mumol litre-1 and of dehydro-nor-ketamine 3.2 +/- 1.9 mumol litre-1.,Ketamine infusions: pharmacokinetics and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526385/),[μM] / [l],4.7,15766,DB01221,Ketamine
,526385,Maximum concentration,Maximum concentration of nor-ketamine was 4.7 +/- 2.4 mumol litre-1 and of dehydro-nor-ketamine 3.2 +/- 1.9 mumol litre-1.,Ketamine infusions: pharmacokinetics and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526385/),[μM] / [l],3.2,15767,DB01221,Ketamine
,3685398,Biliary,"Biliary and urinary excretion within 5.5 h amounted to 15 and 2%, respectively, of the intraduodenally administered N-acetyl- 3H leukotriene E4 in animals anesthetized with ketamine.",Enterohepatic circulation of N-acetyl-leukotriene E4. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3685398/),%,15,18363,DB01221,Ketamine
,3685398,urinary excretion,"Biliary and urinary excretion within 5.5 h amounted to 15 and 2%, respectively, of the intraduodenally administered N-acetyl- 3H leukotriene E4 in animals anesthetized with ketamine.",Enterohepatic circulation of N-acetyl-leukotriene E4. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3685398/),%,2,18364,DB01221,Ketamine
,16415315,mode,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],35.8,18659,DB01221,Ketamine
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],35.8,18660,DB01221,Ketamine
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],11.5,18661,DB01221,Ketamine
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],111.1,18662,DB01221,Ketamine
,27266990,unbound area under the concentration curve,"After 23 μmol/kg i.p. bolus injection, the prodrugs' unbound area under the concentration curve in brain was 0.3 nmol/g × min, whereas the parent drugs could not reach the brain.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[nM] / [g·min],0.3,19802,DB01221,Ketamine
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],521.4,19803,DB01221,Ketamine
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],126.9,19804,DB01221,Ketamine
,27266990,concentrations,"The combination of competing transporter substrates for LAT1, l-tryptophan, and for organic anion transporting polypeptides, probenecid, decreased the brain concentrations to 352.4 ± 44.5 and 70.9 ± 7.0 pmol/g, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),,35,19805,DB01221,Ketamine
,16379643,MAC,The MAC of isoflurane was 1.43 +/- 0.18% (mean +/- SD).,"Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),%,1.43,23068,DB01221,Ketamine
,16379643,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg],371.3,23069,DB01221,Ketamine
,16379643,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg],"4,060.3",23070,DB01221,Ketamine
,16379643,clearance,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg·min],58.2,23071,DB01221,Ketamine
,16379643,terminal half-life,Norketamine rapidly appeared in plasma following ketamine administration and had a terminal half-life of 63.6 +/- 23.9 minutes.,"Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),min,63.6,23072,DB01221,Ketamine
,24977293,absolute bioavailability,"The median (90% CI lower, upper limit) absolute bioavailability of sublingual ketamine was 29% (27, 31%).",The absolute bioavailability of racemic ketamine from a novel sublingual formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977293/),%,29,24734,DB01221,Ketamine
,24977293,time of the peak plasma concentration,The first quantifiable plasma ketamine concentration was observed within 5 min for all eight participants for both routes of administration and the median (min–max) time of the peak plasma concentration was 0.75 h (0.25–1.0 h) after sublingual administration.,The absolute bioavailability of racemic ketamine from a novel sublingual formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977293/),h,0.75,24735,DB01221,Ketamine
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,64.8,26609,DB01221,Ketamine
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,60,26610,DB01221,Ketamine
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,56.6,26611,DB01221,Ketamine
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,50.3,26612,DB01221,Ketamine
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.037,26613,DB01221,Ketamine
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.515,26614,DB01221,Ketamine
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],85.4,26615,DB01221,Ketamine
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],128.0,26616,DB01221,Ketamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,12.1,26617,DB01221,Ketamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.9,26618,DB01221,Ketamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,72.1,26619,DB01221,Ketamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,69.9,26620,DB01221,Ketamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,2.8,26621,DB01221,Ketamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,6.3,26622,DB01221,Ketamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,10.9,26623,DB01221,Ketamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26624,DB01221,Ketamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26625,DB01221,Ketamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.2,26626,DB01221,Ketamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,15.1,26627,DB01221,Ketamine
,10530900,distribution t1/2,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),min,2.5,28128,DB01221,Ketamine
,10530900,elimination t1/2,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),min,43,28129,DB01221,Ketamine
,10530900,apparent volume of distribution,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),[ml] / [kg],1474,28130,DB01221,Ketamine
,10530900,clearance,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),[ml] / [kg·min],33,28131,DB01221,Ketamine
,17359455,Maximal ketamine concentration (C(max)),Maximal ketamine concentration (C(max)) of 2.93 +/- 0.61 microg/ml was reached at 12.5 +/- 2.50 min and thereafter ketamine concentrations decreased rapidly.,Pharmacokinetics of intramuscular ketamine in young ostriches premedicated with romifidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17359455/),[μg] / [ml],2.93,28894,DB01221,Ketamine
,17359455,elimination half-life (t(1/2 z)),The elimination half-life (t(1/2 z)) obtained was 62.37 +/- 17.37 min and mean residence time (MRT) was 77.33 +/- 19.12 min.,Pharmacokinetics of intramuscular ketamine in young ostriches premedicated with romifidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17359455/),min,62.37,28895,DB01221,Ketamine
,17359455,mean residence time (MRT),The elimination half-life (t(1/2 z)) obtained was 62.37 +/- 17.37 min and mean residence time (MRT) was 77.33 +/- 19.12 min.,Pharmacokinetics of intramuscular ketamine in young ostriches premedicated with romifidine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17359455/),min,77.33,28896,DB01221,Ketamine
,17359455,area under the curve (AUC),The area under the curve (AUC) was 114.19 +/- 15.76 microg x min/ml.,Pharmacokinetics of intramuscular ketamine in young ostriches premedicated with romifidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17359455/),[min·μg] / [ml],114.19,28897,DB01221,Ketamine
,16167314,LOD,The LOD for all enantiomers is 0.01 microg/mL.,Characterization of the stereoselective biotransformation of ketamine to norketamine via determination of their enantiomers in equine plasma by capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16167314/),[μg] / [ml],0.01,28989,DB01221,Ketamine
,19290941,volume of the central compartment (V(c),"Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min).",Pharmacokinetics of ketamine and its metabolite norketamine administered at a sub-anesthetic dose together with xylazine to calves prior to castration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290941/),[ml] / [kg],132.82,32523,DB01221,Ketamine
,19290941,distribution clearance (CL(D),"Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min).",Pharmacokinetics of ketamine and its metabolite norketamine administered at a sub-anesthetic dose together with xylazine to calves prior to castration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290941/),[ml] / [kg·min],15.49,32524,DB01221,Ketamine
,19290941,volume of the peripheral compartment (V(T),"Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min).",Pharmacokinetics of ketamine and its metabolite norketamine administered at a sub-anesthetic dose together with xylazine to calves prior to castration. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290941/),[ml] / [kg],257.05,32525,DB01221,Ketamine
,19290941,CL(2M),"Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min).",Pharmacokinetics of ketamine and its metabolite norketamine administered at a sub-anesthetic dose together with xylazine to calves prior to castration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290941/),[ml] / [kg·min],8.56,32526,DB01221,Ketamine
,19290941,CL(o),"Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min).",Pharmacokinetics of ketamine and its metabolite norketamine administered at a sub-anesthetic dose together with xylazine to calves prior to castration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290941/),[ml] / [kg·min],16.41,32527,DB01221,Ketamine
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB01221,Ketamine
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB01221,Ketamine
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB01221,Ketamine
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB01221,Ketamine
,25448584,total clearance,"Typical population parameters were: total clearance: 60.6 ×(weight/70)(0.75)L/h, intercompartmental clearance: 73.2 ×(weight/70)(0.75)L/h, central distribution volume: 57.3 ×(weight/70)L, and peripheral distribution volume: 152 ×(weight/70)L.",Population pharmacokinetics of ketamine in children with heart disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448584/),[l] / [h],60.6,35721,DB01221,Ketamine
,25448584,intercompartmental clearance,"Typical population parameters were: total clearance: 60.6 ×(weight/70)(0.75)L/h, intercompartmental clearance: 73.2 ×(weight/70)(0.75)L/h, central distribution volume: 57.3 ×(weight/70)L, and peripheral distribution volume: 152 ×(weight/70)L.",Population pharmacokinetics of ketamine in children with heart disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448584/),[l] / [h],73.2,35722,DB01221,Ketamine
,25448584,central distribution volume,"Typical population parameters were: total clearance: 60.6 ×(weight/70)(0.75)L/h, intercompartmental clearance: 73.2 ×(weight/70)(0.75)L/h, central distribution volume: 57.3 ×(weight/70)L, and peripheral distribution volume: 152 ×(weight/70)L.",Population pharmacokinetics of ketamine in children with heart disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448584/),l,57.3,35723,DB01221,Ketamine
,25448584,peripheral distribution volume,"Typical population parameters were: total clearance: 60.6 ×(weight/70)(0.75)L/h, intercompartmental clearance: 73.2 ×(weight/70)(0.75)L/h, central distribution volume: 57.3 ×(weight/70)L, and peripheral distribution volume: 152 ×(weight/70)L.",Population pharmacokinetics of ketamine in children with heart disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448584/),l,152,35724,DB01221,Ketamine
,14972713,flow rate,The probes were perfused with isotonic phosphate buffer saline (pH 7.4) at a flow rate of 2 microl/min.,Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),[μl] / [min],2,35813,DB01221,Ketamine
,14972713,terminal elimination half-life,Vitreal terminal elimination half-life of GCV was found to be similar with all three doses and ranged from 325 to 401 min.,Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,325 to 401,35814,DB01221,Ketamine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,112,35815,DB01221,Ketamine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,41.9,35816,DB01221,Ketamine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,33.5,35817,DB01221,Ketamine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,356,35818,DB01221,Ketamine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,341,35819,DB01221,Ketamine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,324,35820,DB01221,Ketamine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,185,35821,DB01221,Ketamine
,30211770,half-life,"Ketamine's half-life of ∼2 h cannot explain antidepressant effects that last for 1 week, suggesting the triggering of long-lasting neuroplasticity.","(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30211770/),h,∼2,39737,DB01221,Ketamine
,33128208,absolute bioavailability,"The absolute bioavailability of 56 and 84 mg of intranasal esketamine is 54 and 51%, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),%,54,40559,DB01221,Ketamine
,33128208,absolute bioavailability,"The absolute bioavailability of 56 and 84 mg of intranasal esketamine is 54 and 51%, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),%,51,40560,DB01221,Ketamine
,33128208,volume at steady state,"Esketamine volume at steady state and clearance were 752 L and 114 L/h, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),l,752,40561,DB01221,Ketamine
,33128208,clearance,"Esketamine volume at steady state and clearance were 752 L and 114 L/h, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),[l] / [h],114,40562,DB01221,Ketamine
,33128208,volume at steady state,"Noresketamine volume at steady state and apparent clearance were 185 L and 38 L/h, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),l,185,40563,DB01221,Ketamine
,33128208,apparent clearance,"Noresketamine volume at steady state and apparent clearance were 185 L and 38 L/h, respectively.",Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128208/),[l] / [h],38,40564,DB01221,Ketamine
,29293004,unbound brain/unbound plasma levels,"Preclinical pharmacokinetics revealed unbound brain/unbound plasma levels approaching unity and good oral bioavailability resulting in an average concentration at steady state (Cav,ss) predicted human dose of 30 mg once daily (q.d.).","Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29293004/),,unity,41269,DB01221,Ketamine
below,34365190,detection limits,The developed methods provided detection limits below 100 ng L-1 for all target analytes and high precision (below 4% RSD intraday).,"Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34365190/),[ng] / [l],100,41389,DB01221,Ketamine
,10568703,total amount of,The total amount of antibody that was released was similar in vitro (25.9%) and in vivo (32.4%).,Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10568703/),%,25.9,42145,DB01221,Ketamine
,10568703,total amount of,The total amount of antibody that was released was similar in vitro (25.9%) and in vivo (32.4%).,Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10568703/),%,32.4,42146,DB01221,Ketamine
,10568703,initial,"RhuMAb HER2 (Group 2) was cleared slowly from the vitreous compartment, with initial and terminal half-lives of 0.9 and 5.6 days, respectively.",Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10568703/),d,0.9,42147,DB01221,Ketamine
,10568703,terminal half-lives,"RhuMAb HER2 (Group 2) was cleared slowly from the vitreous compartment, with initial and terminal half-lives of 0.9 and 5.6 days, respectively.",Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10568703/),d,5.6,42148,DB01221,Ketamine
,22298759,total runtime,"Chromatographic separation is performed on a C(18) column using a mobile phase containing an acetonitrile-methanol-10 mM sodium heptanesulfonate buffer adjusted to pH 3, with glacial acetic acid (44:10:46, v:v) at a detection wavelength of 210 nm, with a total runtime of 10 min.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),min,10,42799,DB01221,Ketamine
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],17.8,42800,DB01221,Ketamine
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],10.3,42801,DB01221,Ketamine
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],15.1,42802,DB01221,Ketamine
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,76.1,42803,DB01221,Ketamine
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,91.0,42804,DB01221,Ketamine
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,78.2,42805,DB01221,Ketamine
,30488740,absolute bioavailability,"(2R,6R)-hydroxynorketamine had absolute bioavailability between 46-52% in mice, 42% in rats, and 58% in dogs.","Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30488740/),%,46-52,43746,DB01221,Ketamine
,30488740,absolute bioavailability,"(2R,6R)-hydroxynorketamine had absolute bioavailability between 46-52% in mice, 42% in rats, and 58% in dogs.","Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30488740/),%,42,43747,DB01221,Ketamine
,30488740,absolute bioavailability,"(2R,6R)-hydroxynorketamine had absolute bioavailability between 46-52% in mice, 42% in rats, and 58% in dogs.","Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30488740/),%,58,43748,DB01221,Ketamine
,30488740,relative oral bioavailability,"Compared to intraperitoneal injection in mice, the relative oral bioavailability of (2R,6R)-hydroxynorketamine was 62%, which was not improved by any of the candidate prodrugs tested.","Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30488740/),%,62,43749,DB01221,Ketamine
,30488740,brain to plasma ratios,"Following oral administration, (2R,6R)-hydroxynorketamine readily penetrated the brain, with brain to plasma ratios between 0.67-1.2 in mice and rats.","Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30488740/),,0.67-1.2,43750,DB01221,Ketamine
,10564058,oral bioavailability,"The mean oral bioavailability of clomipramine was 24.8% and 29.7%, respectively, in conscious rats and in rats anesthetized with ketamine/xylazine (30/3 mg/kg).",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,24.8,44100,DB01221,Ketamine
,10564058,oral bioavailability,"The mean oral bioavailability of clomipramine was 24.8% and 29.7%, respectively, in conscious rats and in rats anesthetized with ketamine/xylazine (30/3 mg/kg).",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,29.7,44101,DB01221,Ketamine
,10564058,absolute bioavailability,"When given sublingually in isotonic saline at a dose of 50 mg/kg, clomipramine was rapidly absorbed, and the mean absolute bioavailability (36.2%) was increased over oral dosing.",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,36.2,44102,DB01221,Ketamine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],2258,44103,DB01221,Ketamine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],1891,44104,DB01221,Ketamine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],3303,44105,DB01221,Ketamine
,10564058,bioavailability,"Sublingual administration (5 mg/kg doses) of clomipramine formulated with a permeation enhancer, 2-hydroxypropyl beta-cyclodextrin, further increased the sublingual bioavailability to 57.1%.",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,57.1,44106,DB01221,Ketamine
,12516077,T(1/2beta),The plasma concentration of ketamine biexponentially declined after the administration by injection; the value of T(1/2beta) for ketamine was approximately 120 min.,Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),min,120,44749,DB01221,Ketamine
,12516077,bioavailability,"The bioavailability of the tablet was estimated to be approximately 20%; the area under the plasma concentration-time curve, (AUC)(0-->8 h), of norketamine was approximately 500 ng h/ml in both enantiomers.",Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),%,20,44750,DB01221,Ketamine
,12516077,"area under the plasma concentration-time curve, (AUC)(","The bioavailability of the tablet was estimated to be approximately 20%; the area under the plasma concentration-time curve, (AUC)(0-->8 h), of norketamine was approximately 500 ng h/ml in both enantiomers.",Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),[h·ng] / [ml],500,44751,DB01221,Ketamine
,12516077,bioavailabilities,The bioavailabilities of the sublingual tablet and the suppository were estimated to both be approximately 30%; the AUC(0-->8 h) of norketamine was 280-460 ng h/ml in both enantiomers.,Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),%,30,44752,DB01221,Ketamine
,12516077,AUC(0-->8 h),The bioavailabilities of the sublingual tablet and the suppository were estimated to both be approximately 30%; the AUC(0-->8 h) of norketamine was 280-460 ng h/ml in both enantiomers.,Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),[h·ng] / [ml],280-460,44753,DB01221,Ketamine
,12516077,bioavailability,"The bioavailability of the nasal spray was estimated to be approximately 45%, which was the highest value among the preparations tested, and the AUC(0-->6 h) of norketamine was low (approximately 100 ng h/ml) in both enantiomers.",Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),%,45,44754,DB01221,Ketamine
,12516077,AUC(0-->6 h),"The bioavailability of the nasal spray was estimated to be approximately 45%, which was the highest value among the preparations tested, and the AUC(0-->6 h) of norketamine was low (approximately 100 ng h/ml) in both enantiomers.",Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516077/),[h·ng] / [ml],100,44755,DB01221,Ketamine
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,2.9,49769,DB01221,Ketamine
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,3.8,49770,DB01221,Ketamine
,18085156,peak levels,"The lowest mean peak levels of plasma cortisol (82.53 +/- 6.04 nmol l(-1)), the most rapid return of plasma cortisol levels to baseline values (1.92 +/- 1.11 h), and the lowest occurrence of stress behaviours (2.38 +/- 5.83%) were noted in the SLA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],82.53,50856,DB01221,Ketamine
,18085156,peak levels,"The highest mean peak levels plasma cortisol (113.86 +/- 25.65 nmol l(-1)), the slowest return of plasma cortisol levels to baseline values (3.83 +/- 2.18 h) and the most frequent occurrence of stress behaviours (65.48 +/- 28.72%) were observed in the LA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],113.86,50857,DB01221,Ketamine
,26171236,half-life of drug elimination during the terminal phase (t 1/2),"After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t 1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (V d) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%.","The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171236/),h,8.0,51968,DB01221,Ketamine
,26171236,apparent volume of distribution (V d),"After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t 1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (V d) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%.","The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171236/),[ml] / [kg],7352,51969,DB01221,Ketamine
,26171236,clearance (Cl),"After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t 1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (V d) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%.","The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171236/),[ml] / [h·kg],704,51970,DB01221,Ketamine
,26171236,bioavailability,"After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t 1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (V d) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%.","The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171236/),%,46.3,51971,DB01221,Ketamine
,31881397,fu,"Toxicokinetic comparison of the five compounds gave a fu between 0.54 and 0.84, with ketamine being the most bound and deschloroketamine being the least bound, in accordance with the logP of the compounds.",Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31881397/),,0.54 and 0.84,53191,DB01221,Ketamine
,31881397,"hepatic clearance, CLparallel","The IVIVE of hepatic clearance, CLparallel-tube, gave values from 18.1 to 5.44 mL/min/kg for ketamine and methoxetamine, respectively.",Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31881397/),[ml] / [kg·min],18.1 to 5.44,53192,DB01221,Ketamine
,2051573,I (,"Two hours following the end of the ketamine infusion, plasma ketamine levels decreased to 14% of the control value (0.81 micrograms.ml-1), while metabolite I (K1) was still about 1.8 micrograms.","[A clinical study on total intravenous anesthesia with droperidol, fentanyl and ketamine--2. Pharmacokinetics following the end of continuous ketamine infusion]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051573/),μg,1.8,54434,DB01221,Ketamine
,2051573,K1),"Two hours following the end of the ketamine infusion, plasma ketamine levels decreased to 14% of the control value (0.81 micrograms.ml-1), while metabolite I (K1) was still about 1.8 micrograms.","[A clinical study on total intravenous anesthesia with droperidol, fentanyl and ketamine--2. Pharmacokinetics following the end of continuous ketamine infusion]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051573/),μg,1.8,54435,DB01221,Ketamine
,25724645,oral bioavailability,"The oral bioavailability of S-ketamine was low, 8% (11% interindividual variability), and its clearance was high, 95 L/h/70 kg (13% interindividual variability).",Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724645/),%,8,56404,DB01221,Ketamine
,25724645,clearance,"The oral bioavailability of S-ketamine was low, 8% (11% interindividual variability), and its clearance was high, 95 L/h/70 kg (13% interindividual variability).",Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724645/),[l] / [70·h·kg],95,56405,DB01221,Ketamine
,11719729,slope,"Two infusion cycles with linearly increasing targets [slope, 0.1 microg x ml(-1) x min(-1) for S(+)-ketamine and 0.2 microg x ml(-1) x min(-1) for racemic ketamine] were administered.",Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[μg] / [min·ml],0.1,56653,DB01221,Ketamine
,11719729,slope,"Two infusion cycles with linearly increasing targets [slope, 0.1 microg x ml(-1) x min(-1) for S(+)-ketamine and 0.2 microg x ml(-1) x min(-1) for racemic ketamine] were administered.",Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[μg] / [min·ml],0.2,56654,DB01221,Ketamine
,11719729,clearance,S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05).,Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[ml] / [kg·min],26.3,56655,DB01221,Ketamine
,11719729,clearance,S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05).,Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[ml] / [kg·min],14.8,56656,DB01221,Ketamine
,11719729,clearance,S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05).,Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[ml] / [kg·min],13.8,56657,DB01221,Ketamine
,11719729,clearance,"Furthermore, the clearance of the S (+)-ketamine was smaller in the racemate (18.5 +/- 0.7 ml x kg(-1) x min(-1); P <.05) than for the pure isomer.",Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719729/),[ml] / [kg·min],18.5,56658,DB01221,Ketamine
<,21551257,IC(50),"However, IC(50) values were <100 μM only for UGT2B4, UGT2B7, and UGT2B15.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,100,59703,DB01221,Ketamine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,5.8,59704,DB01221,Ketamine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,4.6,59705,DB01221,Ketamine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,3.5,59706,DB01221,Ketamine
,21287740,peak time,"The peak time and the peak concentration of ketamine in serum were (40.950 +/- 12.098) min and (9.015 +/- 1.344) microg/mL, respectively.",[Toxicokinetics of ketamine in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21287740/),min,40.950,59739,DB01221,Ketamine
,21287740,peak concentration,"The peak time and the peak concentration of ketamine in serum were (40.950 +/- 12.098) min and (9.015 +/- 1.344) microg/mL, respectively.",[Toxicokinetics of ketamine in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21287740/),[μg] / [ml],9.015,59740,DB01221,Ketamine
,21287740,elimination half-time,The elimination half-time of ketamine in rabbits was (430.370 +/- 28.436) min.,[Toxicokinetics of ketamine in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21287740/),min,430.370,59741,DB01221,Ketamine
,4029219,plasma half-life,The plasma half-life of ketamine ranged from 0.74 h in rabbits with normal renal function to 2.6 h in the animals with severe renal impairment.,Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029219/),h,0.74,62890,DB01221,Ketamine
,4029219,plasma half-life,The plasma half-life of ketamine ranged from 0.74 h in rabbits with normal renal function to 2.6 h in the animals with severe renal impairment.,Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029219/),h,2.6,62891,DB01221,Ketamine
,21040381,elimination half-lives,"The harmonic mean elimination half-lives (± pseudo SD) for X, X with K and K were 12.9 ± 1.2, 11.2 ± 3.1 and 10.6 ± 2.8 minutes, respectively.",Effect of sub-anesthetic xylazine and ketamine ('ketamine stun') administered to calves immediately prior to castration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040381/),min,12.9,62976,DB01221,Ketamine
,21040381,elimination half-lives,"The harmonic mean elimination half-lives (± pseudo SD) for X, X with K and K were 12.9 ± 1.2, 11.2 ± 3.1 and 10.6 ± 2.8 minutes, respectively.",Effect of sub-anesthetic xylazine and ketamine ('ketamine stun') administered to calves immediately prior to castration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040381/),min,11.2,62977,DB01221,Ketamine
,21040381,elimination half-lives,"The harmonic mean elimination half-lives (± pseudo SD) for X, X with K and K were 12.9 ± 1.2, 11.2 ± 3.1 and 10.6 ± 2.8 minutes, respectively.",Effect of sub-anesthetic xylazine and ketamine ('ketamine stun') administered to calves immediately prior to castration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040381/),min,10.6,62978,DB01221,Ketamine
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.4,71665,DB01221,Ketamine
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],2.6,71666,DB01221,Ketamine
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.7,71667,DB01221,Ketamine
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],5.5,71668,DB01221,Ketamine
,30929859,plasma concentration at steady state,"The plasma concentration at steady state was 1018.7 ng/mL, with an estimated clearance of 1.96 L/kg/h after up-titration.",Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929859/),[ng] / [ml],1018.7,71979,DB01221,Ketamine
,30929859,clearance,"The plasma concentration at steady state was 1018.7 ng/mL, with an estimated clearance of 1.96 L/kg/h after up-titration.",Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929859/),[l] / [h·kg],1.96,71980,DB01221,Ketamine
,30929859,Vd,"The Vd was 14.18 L/kg, the ke was 0.14 hr-1, and the t½ was 5 hours.",Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929859/),[l] / [kg],14.18,71981,DB01221,Ketamine
,30929859,ke,"The Vd was 14.18 L/kg, the ke was 0.14 hr-1, and the t½ was 5 hours.",Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929859/),1/[h],0.14,71982,DB01221,Ketamine
,30929859,t½,"The Vd was 14.18 L/kg, the ke was 0.14 hr-1, and the t½ was 5 hours.",Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929859/),h,5,71983,DB01221,Ketamine
,8968410,plasma AUC ratios,"Fetal to maternal plasma AUC ratios were 0.09, 0.07, and 0.16 after the 1, 10, or 40 mg/kg dose, respectively.","Distribution of 2,4-dichlorophenoxyacetic acid (2,4-D) in maternal and fetal rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968410/),,0.09,72178,DB01221,Ketamine
,8968410,plasma AUC ratios,"Fetal to maternal plasma AUC ratios were 0.09, 0.07, and 0.16 after the 1, 10, or 40 mg/kg dose, respectively.","Distribution of 2,4-dichlorophenoxyacetic acid (2,4-D) in maternal and fetal rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968410/),,0.07,72179,DB01221,Ketamine
,8968410,plasma AUC ratios,"Fetal to maternal plasma AUC ratios were 0.09, 0.07, and 0.16 after the 1, 10, or 40 mg/kg dose, respectively.","Distribution of 2,4-dichlorophenoxyacetic acid (2,4-D) in maternal and fetal rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968410/),,0.16,72180,DB01221,Ketamine
,21355949,Bioavailability,"Bioavailability of the oral formulation was 0.45 (90% CI 0.33, 0.58).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),,0.45,72933,DB01221,Ketamine
,21355949,Absorption half-time,"Absorption half-time was 59 (90% CI 29.4, 109.2) min and had high between-subject variability (BSV 148%).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),min,59,72934,DB01221,Ketamine
,21355949,central volume,"Population parameter estimates, standardized to a 70-kg person, were central volume 21.1 (BSV 47.1%) l·70 kg(-1), peripheral volume of distribution 109 (27.5%) l·70 kg(-1), clearance 81.3 (46.1%) l·h(-1)·70 kg(-1), and inter-compartment clearance 259 (50.1%) l·h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·kg],21.1,72935,DB01221,Ketamine
,21355949,peripheral volume of distribution,"Population parameter estimates, standardized to a 70-kg person, were central volume 21.1 (BSV 47.1%) l·70 kg(-1), peripheral volume of distribution 109 (27.5%) l·70 kg(-1), clearance 81.3 (46.1%) l·h(-1)·70 kg(-1), and inter-compartment clearance 259 (50.1%) l·h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·kg],109,72936,DB01221,Ketamine
,21355949,clearance,"Population parameter estimates, standardized to a 70-kg person, were central volume 21.1 (BSV 47.1%) l·70 kg(-1), peripheral volume of distribution 109 (27.5%) l·70 kg(-1), clearance 81.3 (46.1%) l·h(-1)·70 kg(-1), and inter-compartment clearance 259 (50.1%) l·h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·h·kg],81.3,72937,DB01221,Ketamine
,21355949,inter-compartment clearance,"Population parameter estimates, standardized to a 70-kg person, were central volume 21.1 (BSV 47.1%) l·70 kg(-1), peripheral volume of distribution 109 (27.5%) l·70 kg(-1), clearance 81.3 (46.1%) l·h(-1)·70 kg(-1), and inter-compartment clearance 259 (50.1%) l·h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·h·kg],259,72938,DB01221,Ketamine
,21355949,volume,"Under the assumption that all ketamine was converted to norketamine, the volume of the metabolite was 151.9 (BSV 39.1%) l·70 kg(-1) with an elimination clearance of 64.4 (BSV 63.4%) l·h(-1) ·70 kg(-1) and a rate constant for intermediate compartments of 26.2 (BSV 52.1%) h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·kg],151.9,72939,DB01221,Ketamine
,21355949,elimination clearance,"Under the assumption that all ketamine was converted to norketamine, the volume of the metabolite was 151.9 (BSV 39.1%) l·70 kg(-1) with an elimination clearance of 64.4 (BSV 63.4%) l·h(-1) ·70 kg(-1) and a rate constant for intermediate compartments of 26.2 (BSV 52.1%) h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),[l] / [70·h·kg],64.4,72940,DB01221,Ketamine
,21355949,rate constant for intermediate compartments,"Under the assumption that all ketamine was converted to norketamine, the volume of the metabolite was 151.9 (BSV 39.1%) l·70 kg(-1) with an elimination clearance of 64.4 (BSV 63.4%) l·h(-1) ·70 kg(-1) and a rate constant for intermediate compartments of 26.2 (BSV 52.1%) h(-1)·70 kg(-1).",Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),1/[70·h·kg],26.2,72941,DB01221,Ketamine
,21355949,peak ratio,The peak ratio of norketamine/ketamine at 1 h is 2.8 after oral administration allowing an analgesic contribution from the metabolite at this time.,Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),,2.8,72942,DB01221,Ketamine
<,21355949,relative bioavailability,There is low relative bioavailability (<0.5) and slow variable absorption.,Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355949/),,0.5,72943,DB01221,Ketamine
,25822925,return of righting reflex,All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78-131] R1 vs 996 seconds [IQR 840-1304] ketamine in rats; P < 0.01).,Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822925/),seconds,87,76794,DB01221,Ketamine
,25822925,return of righting reflex,All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78-131] R1 vs 996 seconds [IQR 840-1304] ketamine in rats; P < 0.01).,Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822925/),seconds,996,76795,DB01221,Ketamine
,25822925,LD50 R1,"The LD50 was comparable to that of ketamine (LD50 R1 50.2 mg/kg [95% confidence interval, 30-63]).",Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822925/),[mg] / [kg],50.2,76796,DB01221,Ketamine
,25822925,clearance,"For all analogs, hydrolysis to sole carboxylic acid derivatives was most rapid in vivo (clearance 1.61 L/kg/min R1 [IQR 0.40-2.42]), followed by whole blood and then plasma.",Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822925/),[l] / [kg·min],1.61,76797,DB01221,Ketamine
,22575567,onset/offset half-life,The concentration of S(+)-ketamine causing a 1 L/min increase in CO was 243 ± 54 ng/mL with an onset/offset half-life of 1.3 ± 0.21 minutes.,The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575567/),min,1.3,76831,DB01221,Ketamine
,22575567,time constant,The inhibitory component was slow (time constant of 67.2 ± 17.0 minutes).,The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575567/),min,67.2,76832,DB01221,Ketamine
,2611068,peak concentration,"The absorption of ketamine was found to be relatively fast, with a median peak concentration of 160 ng ml-1 (range 96-250 ng ml-1) at 0.75 h (range 0.50-1.00 h) after administration.",Pharmacokinetics of rectal ketamine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611068/),[ng] / [ml],160,80417,DB01221,Ketamine
,2611068,half-lives,"The medians of the half-lives of ketamine and norketamine were 3.15 h and 2.56 h, respectively (range 1.57-4.95 h and 1.47-5.30 h, respectively).",Pharmacokinetics of rectal ketamine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611068/),h,3.15,80418,DB01221,Ketamine
,2611068,half-lives,"The medians of the half-lives of ketamine and norketamine were 3.15 h and 2.56 h, respectively (range 1.57-4.95 h and 1.47-5.30 h, respectively).",Pharmacokinetics of rectal ketamine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611068/),h,2.56,80419,DB01221,Ketamine
,2611068,half-lives,"The medians of the half-lives of ketamine and norketamine were 3.15 h and 2.56 h, respectively (range 1.57-4.95 h and 1.47-5.30 h, respectively).",Pharmacokinetics of rectal ketamine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611068/),h,1.47-5.30,80420,DB01221,Ketamine
,8807019,steady-state volume of distribution,Mean steady-state volume of distribution of methohexital in the anesthetized dogs was 1.50 L/kg of body weight and mean elimination clearance was 10.2 ml/kg/min.,Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807019/),[l] / [kg],1.50,84402,DB01221,Ketamine
,8807019,elimination clearance,Mean steady-state volume of distribution of methohexital in the anesthetized dogs was 1.50 L/kg of body weight and mean elimination clearance was 10.2 ml/kg/min.,Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807019/),[ml] / [kg·min],10.2,84403,DB01221,Ketamine
≥,28724494,effective plasma concentrations,"We hypothesized that TFS in rhesus macaques would provide at least 4 d of effective plasma concentrations (assumed to be ≥ 0.2 ng/mL, based on human studies).","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],0.2,85804,DB01221,Ketamine
,28724494,maximal plasma concentration,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],1.95,85805,DB01221,Ketamine
,28724494,maximal plasma concentration,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],4.19,85806,DB01221,Ketamine
,28724494,AUC,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[h] / [ml·ng],227.3,85807,DB01221,Ketamine
,28724494,AUC,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[h] / [ml·ng],447.0,85808,DB01221,Ketamine
,28724494,terminal elimination half-life,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),h,93.7,85809,DB01221,Ketamine
,28724494,terminal elimination half-life,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),h,98.8,85810,DB01221,Ketamine
,18613930,plasma concentration,Arousal to light touch or voice appears to occur at a mean plasma concentration of 0.5 mg.l(-1) in both children and adults.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),,0.5,86795,DB01221,Ketamine
,18613930,steady-state target concentration,h(-1) from 1 to 2 h resulted in a steady-state target concentration of 3 mg.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),mg,3,86796,DB01221,Ketamine
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),h,1.5,86797,DB01221,Ketamine
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),min,30,86798,DB01221,Ketamine
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),min,55,86799,DB01221,Ketamine
,18613930,steady-state concentrations,Children require higher infusion rates than adults to maintain steady-state concentrations of 3 mg.l(-1) and have shorter context sensitive half-times than adults after prolonged infusion.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),[mg] / [l],3,86800,DB01221,Ketamine
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.90,86872,DB01221,Ketamine
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.24,86873,DB01221,Ketamine
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.19,86874,DB01221,Ketamine
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],2.84,86875,DB01221,Ketamine
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],1.99,86876,DB01221,Ketamine
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],71.7,86877,DB01221,Ketamine
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],33.4,86878,DB01221,Ketamine
,19366273,bioavailabilities,"Oral and sublingual bioavailabilities [median (interquartile range)] were 24% (17-27%) and 24% (19-49%), respectively.","Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19366273/),%,24,88640,DB01221,Ketamine
,19366273,bioavailabilities,"Oral and sublingual bioavailabilities [median (interquartile range)] were 24% (17-27%) and 24% (19-49%), respectively.","Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19366273/),%,24,88641,DB01221,Ketamine
,19366273,area under the plasma concentration-time curve from baseline to 8 hours ratios,"The mean norketamine/ketamine area under the plasma concentration-time curve from baseline to 8 hours ratios were 5 and 2.1 after oral or sublingual administration, respectively.","Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19366273/),,5,88642,DB01221,Ketamine
,19366273,area under the plasma concentration-time curve from baseline to 8 hours ratios,"The mean norketamine/ketamine area under the plasma concentration-time curve from baseline to 8 hours ratios were 5 and 2.1 after oral or sublingual administration, respectively.","Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19366273/),,2.1,88643,DB01221,Ketamine
,16616769,t(1/2),"Both the uncompetitive NMDA antagonist ketamine and the glycine(B) antagonist MRZ 2/576 inhibited neuronal responses to iontophoretic NMDA in anaesthetised rats with the time course consistent with their known pharmacokinetics (t(1/2) approximately 10-12min, similar in control and nerve-injured rats).",The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616769/),min,10-12,90636,DB01221,Ketamine
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,0,94814,DB01221,Ketamine
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,11.8,94815,DB01221,Ketamine
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,6.1,94816,DB01221,Ketamine
,18810393,blood serum concentration,"After administration via drinking water in saline-injected control animals, the hal blood serum concentration was 2.6 +/- 0.45 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],2.6,99177,DB01221,Ketamine
,18810393,serum concentration,"In ket-injected animals, the mean serum concentration of hal amounted to 1.2 +/- 0.44 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],1.2,99178,DB01221,Ketamine
,1911019,apparent uptake rate constants,"The mean apparent uptake rate constants of ketamine for plasma and CSF were 4.17 (SD 1.84) and 5.15 (2.50) h-1, respectively.",Pharmacokinetics and distribution of ketamine after extradural administration to dogs. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911019/),1/[h],4.17,103870,DB01221,Ketamine
,1911019,apparent uptake rate constants,"The mean apparent uptake rate constants of ketamine for plasma and CSF were 4.17 (SD 1.84) and 5.15 (2.50) h-1, respectively.",Pharmacokinetics and distribution of ketamine after extradural administration to dogs. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911019/),1/[h],5.15,103871,DB01221,Ketamine
,1911019,elimination half-life,"The elimination half-life values of the parent drug for both biological fluids were similar (4.3 (2.96) h and 4.6 (3.31) h for plasma and CSF, respectively).",Pharmacokinetics and distribution of ketamine after extradural administration to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911019/),h,4.3,103872,DB01221,Ketamine
,1911019,elimination half-life,"The elimination half-life values of the parent drug for both biological fluids were similar (4.3 (2.96) h and 4.6 (3.31) h for plasma and CSF, respectively).",Pharmacokinetics and distribution of ketamine after extradural administration to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911019/),h,4.6,103873,DB01221,Ketamine
,21381066,Extraction recovery,Extraction recovery was 93% for ketamine and 95% for medetomidine.,Liquid chromatography tandem mass spectrometry for the simultaneous quantitative analysis of ketamine and medetomidine in ovine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21381066/),%,93,105016,DB01221,Ketamine
,21381066,Extraction recovery,Extraction recovery was 93% for ketamine and 95% for medetomidine.,Liquid chromatography tandem mass spectrometry for the simultaneous quantitative analysis of ketamine and medetomidine in ovine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21381066/),%,95,105017,DB01221,Ketamine
,1460754,Plasma half-lives,"Plasma half-lives of ketamine were calculated to be 33 min for distribution phase (alpha phase) and 60 min for elimination phase (beta phase), respectively.","[Pharmacokinetics of ketamine and pentazocine during total intravenous anesthesia with droperidol, pentazocine and ketamine]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1460754/),min,33,106550,DB01221,Ketamine
,1460754,Plasma half-lives,"Plasma half-lives of ketamine were calculated to be 33 min for distribution phase (alpha phase) and 60 min for elimination phase (beta phase), respectively.","[Pharmacokinetics of ketamine and pentazocine during total intravenous anesthesia with droperidol, pentazocine and ketamine]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1460754/),min,60,106551,DB01221,Ketamine
,1460754,Plasma half-lives,"Plasma half-lives of pentazocine were 60 min for alpha phase and 140 min for beta phase, respectively.","[Pharmacokinetics of ketamine and pentazocine during total intravenous anesthesia with droperidol, pentazocine and ketamine]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1460754/),min,60,106552,DB01221,Ketamine
,1460754,Plasma half-lives,"Plasma half-lives of pentazocine were 60 min for alpha phase and 140 min for beta phase, respectively.","[Pharmacokinetics of ketamine and pentazocine during total intravenous anesthesia with droperidol, pentazocine and ketamine]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1460754/),min,140,106553,DB01221,Ketamine
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.001,107259,DB01221,Ketamine
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.619,107260,DB01221,Ketamine
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.184,107261,DB01221,Ketamine
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.118,107262,DB01221,Ketamine
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,156,109115,DB01221,Ketamine
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,227,109116,DB01221,Ketamine
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,13,109117,DB01221,Ketamine
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,23,109118,DB01221,Ketamine
,28339766,MRT,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,26,109119,DB01221,Ketamine
,28339766,MRT,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,5.2,109120,DB01221,Ketamine
,28339766,T½β,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,18,109121,DB01221,Ketamine
,28339766,T½β,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,3,109122,DB01221,Ketamine
,1744940,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,21.65,110196,DB01221,Ketamine
,1744940,clearance (Cl),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14.1,110197,DB01221,Ketamine
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,55.95,110198,DB01221,Ketamine
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,68.03,110199,DB01221,Ketamine
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14,110200,DB01221,Ketamine
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],13.6,110201,DB01221,Ketamine
,25464106,flow rate,"Separation of analytes was performed with a Hypersil C18 column and a mobile phase with acetonitrile and 0.1% formic acid (60/40, v/v) under isocratic conditions at a flow rate of 280μl/min.","Simultaneous detection of ketamine, lorazepam, midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464106/),[μl] / [min],280,112299,DB01221,Ketamine
,18571772,plasma half-life,The tracer had a plasma half-life of 77+/-1.7min and was rapidly taken up by all brain areas.,"Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-the cases of ketamine and haloperidol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18571772/),min,77,112939,DB01221,Ketamine
,34019627,area under the concentrations-time curve ratios,"After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001).",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),,18,116917,DB01221,Ketamine
,34019627,area under the concentrations-time curve ratios,"After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001).",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),,30,116918,DB01221,Ketamine
,34019627,area under the concentrations-time curve ratios,"After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001).",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),,1.7,116919,DB01221,Ketamine
,34019627,area under the concentrations-time curve ratios,"After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001).",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),,3.1,116920,DB01221,Ketamine
,34019627,distribution volumes at steady state,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),[l] / [kg],6.6,116921,DB01221,Ketamine
,34019627,distribution volumes at steady state,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),[l] / [kg],5.6,116922,DB01221,Ketamine
,34019627,terminal half-lives,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),h,5.2,116923,DB01221,Ketamine
,34019627,terminal half-lives,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),h,6.1,116924,DB01221,Ketamine
,34019627,metabolic clearances,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),[ml] / [min],"1,620",116925,DB01221,Ketamine
,34019627,metabolic clearances,"The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively.",Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),[ml] / [min],"1,530",116926,DB01221,Ketamine
,34019627,Bioavailability,Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h.,Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),%,15,116927,DB01221,Ketamine
,34019627,Bioavailability,Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h.,Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),%,19,116928,DB01221,Ketamine
,34019627,terminal half-life,Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h.,Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),h,11,116929,DB01221,Ketamine
,34019627,terminal half-life,Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h.,Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019627/),h,10,116930,DB01221,Ketamine
,8126758,t1/2-alpha,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,1.8,120970,DB01221,Ketamine
,8126758,t1/2-beta,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,27.8,120971,DB01221,Ketamine
,8126758,t1/2-alpha,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,1.35,120972,DB01221,Ketamine
,8126758,t1/2-beta,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,31.6,120973,DB01221,Ketamine
,8126758,coefficient,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],429,120974,DB01221,Ketamine
,8126758,coefficient,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],888,120975,DB01221,Ketamine
,8126758,B,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],429,120976,DB01221,Ketamine
,8126758,B,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],888,120977,DB01221,Ketamine
,8126758,AUC,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [h·ml],"29,800",120978,DB01221,Ketamine
,8126758,AUC,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [h·ml],"42,500",120979,DB01221,Ketamine
,8126758,ClB,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ml] / [kg·min],17.4,120980,DB01221,Ketamine
,8126758,ClB,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ml] / [kg·min],12.1,120981,DB01221,Ketamine
,31929589,Tmax,Non-compartmental pharmacokinetic analysis revealed a rapid (Tmax = 0.25 ± 0.14 h) and complete IN bioavailability (F = 147.65 ± 49.97%).,"Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,0.25,121853,DB01221,Ketamine
,31929589,bioavailability (F,Non-compartmental pharmacokinetic analysis revealed a rapid (Tmax = 0.25 ± 0.14 h) and complete IN bioavailability (F = 147.65 ± 49.97%).,"Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),%,147.65,121854,DB01221,Ketamine
,31929589,T1/2el IV,"Elimination half-life was similar between both administration routes (T1/2el IV = 1.47 ± 0.24 h, T1/2el IN = 1.50 ± 0.97 h).","Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,1.47,121855,DB01221,Ketamine
,31929589,T1/2el IN,"Elimination half-life was similar between both administration routes (T1/2el IV = 1.47 ± 0.24 h, T1/2el IN = 1.50 ± 0.97 h).","Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,1.50,121856,DB01221,Ketamine
,20020418,K(m),"Using non-linear regression, we determined a K(m) value of 577 nM, indicating relatively low threshold enzyme saturation consistent with previous in vivo observation.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),nM,577,122411,DB01221,Ketamine
,20020418,T(1/2),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),min,90,122412,DB01221,Ketamine
,20020418,CL(i),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),[ml] / [min],0.008,122413,DB01221,Ketamine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,238.3,125677,DB01221,Ketamine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,125.9,125678,DB01221,Ketamine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,237.1,125679,DB01221,Ketamine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,194.1,125680,DB01221,Ketamine
,30956016,half-life,"The plasma concentration of ketamine decreased with a half-life of approximately 12 minutes, which was longer than the dose interval.",The course of plasma cortisol concentration after three different doses of ketamine in xylazine-premedicated calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956016/),min,12,125919,DB01221,Ketamine
,29229209,half-life,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),h,1.73,126249,DB01221,Ketamine
,29229209,Cmax,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),[μg] / [ml],64.4,126250,DB01221,Ketamine
,29229209,AUC0-t,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),[μgh] / [ml],196,126251,DB01221,Ketamine
,3970799,pot,The serum ketamine concentrations associated with regaining consciousness and orientation were consistent with an S(+):R(-) isomer potency ratio of 4:1.,Comparative pharmacology of the ketamine isomers. Studies in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970799/),,4,126781,DB01221,Ketamine
,7272143,concentration,"The plasma ketamine concentration associated with analgesia was 150 ng ml-1 following the i.m. dose, but only 40 ng ml-1 after the oral dose.",Pharmacokinetics and analgesic effects of i.m. and oral ketamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272143/),[ng] / [ml],150,127424,DB01221,Ketamine
,7272143,concentration,"The plasma ketamine concentration associated with analgesia was 150 ng ml-1 following the i.m. dose, but only 40 ng ml-1 after the oral dose.",Pharmacokinetics and analgesic effects of i.m. and oral ketamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272143/),[ng] / [ml],40,127425,DB01221,Ketamine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,238.,128253,DB01221,Ketamine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,179.1,128254,DB01221,Ketamine
,29951541,m/z,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,385.3,128255,DB01221,Ketamine
,29951541,m/z,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,159.8,128256,DB01221,Ketamine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,237.3,128257,DB01221,Ketamine
,31837511,MAC-BARsevo,"Mean MAC-BARsevo of the ketamine and placebo were 2.73 ± 0.23% and 2.77 ± 0.31%, respectively and no significant difference was found (p = .638).",Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),%,2.73,129803,DB01221,Ketamine
,31837511,MAC-BARsevo,"Mean MAC-BARsevo of the ketamine and placebo were 2.73 ± 0.23% and 2.77 ± 0.31%, respectively and no significant difference was found (p = .638).",Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),%,2.77,129804,DB01221,Ketamine
,31837511,plasma concentrations,Average ketamine plasma concentrations was 1.54 ± 0.18 μg/mL maintained through the study.,Determination of the minimum alveolar concentration of sevoflurane that blunts adrenergic responses and the effect of a constant rate infusion of ketamine in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31837511/),[μg] / [ml],1.54,129805,DB01221,Ketamine
,33423953,terminal half-life,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),min,44.3,130142,DB01221,Ketamine
,33423953,volume of distribution,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[l] / [kg],0.43,130143,DB01221,Ketamine
,33423953,plasma clearance,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[ml] / [kg·min],7.77,130144,DB01221,Ketamine
,31401049,times to sternal,"The times to sternal, mean 32.3 and 24.6 minutes, for groups KMF and KM, respectively, were not different between the groups.",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,32.3,133019,DB01221,Ketamine
,31401049,times to sternal,"The times to sternal, mean 32.3 and 24.6 minutes, for groups KMF and KM, respectively, were not different between the groups.",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,24.6,133020,DB01221,Ketamine
,31401049,time to standing,"The time to standing, 73 and 36 minutes in groups KMF and KM, respectively, was significantly different (p = 0.002).",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,73,133021,DB01221,Ketamine
,31401049,time to standing,"The time to standing, 73 and 36 minutes in groups KMF and KM, respectively, was significantly different (p = 0.002).",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,36,133022,DB01221,Ketamine
,31401049,duration,The duration of elevated HR compared with baseline was longer in KMF (110 minutes) than in KM (25 minutes) (p < 0.05).,Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,110,133023,DB01221,Ketamine
,31401049,duration,The duration of elevated HR compared with baseline was longer in KMF (110 minutes) than in KM (25 minutes) (p < 0.05).,Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,25,133024,DB01221,Ketamine
,7560249,tmax,"The tmax was 2 to 4 hours after dosing, with nonlinear increases in Cmax and the AUC0-4th for HP 749.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),h,2 to 4,137978,DB01221,Ketamine
,7560249,elimination half life (t1/2),"The calculated elimination half life (t1/2) after oral administration was 7.4 +/- 2.1 hours; however, absorption appeared to influence the terminal phase because the t1/2 after intravenous administration of 10 mg/kg was 1.5 hours.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),h,7.4,137979,DB01221,Ketamine
,7560249,t1/2,"The calculated elimination half life (t1/2) after oral administration was 7.4 +/- 2.1 hours; however, absorption appeared to influence the terminal phase because the t1/2 after intravenous administration of 10 mg/kg was 1.5 hours.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),h,1.5,137980,DB01221,Ketamine
,7560249,Plasma concentration,Plasma concentration of HP 749 2 minutes after intravenous bolus was 26.08 micrograms/mL.,The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),[μg] / [ml],26.08,137981,DB01221,Ketamine
,7560249,t1/2 alpha,"The HP 749 was rapidly distributed (t1/2 alpha = 0.064 +/- 0.033 hours) after intravenous administration, and displayed a VZ of 2.6 +/- 0.85 L/kg.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),h,0.064,137982,DB01221,Ketamine
,7560249,VZ,"The HP 749 was rapidly distributed (t1/2 alpha = 0.064 +/- 0.033 hours) after intravenous administration, and displayed a VZ of 2.6 +/- 0.85 L/kg.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),[l] / [kg],2.6,137983,DB01221,Ketamine
,7560249,CL,"The CL of HP 749 was 20.8 +/- 6.9 mL/min/kg, whereas renal clearance (CLR) of unchanged drug was only 0.13 +/- 0.04 mL/min/kg.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),[ml] / [kg·min],20.8,137984,DB01221,Ketamine
,7560249,renal clearance (CLR),"The CL of HP 749 was 20.8 +/- 6.9 mL/min/kg, whereas renal clearance (CLR) of unchanged drug was only 0.13 +/- 0.04 mL/min/kg.",The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560249/),[ml] / [kg·min],0.13,137985,DB01221,Ketamine
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB01221,Ketamine
,21153031,Maximum hair concentrations (C (max)),"Maximum hair concentrations (C (max)) for ketamine and norketamine were 19.0 ± 6.5 and 18.7 ± 13.3 pg/mg, respectively.",Disposition of ketamine and norketamine in hair after a single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21153031/),[pg] / [mg],19.0,140892,DB01221,Ketamine
,21153031,Maximum hair concentrations (C (max)),"Maximum hair concentrations (C (max)) for ketamine and norketamine were 19.0 ± 6.5 and 18.7 ± 13.3 pg/mg, respectively.",Disposition of ketamine and norketamine in hair after a single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21153031/),[pg] / [mg],18.7,140893,DB01221,Ketamine
,30825333,clearance,Pharmacokinetic parameters determined were clearance 0.025 ± 0.008 L/kg/min; distribution volume 3.3 ± 1.3 L/kg; half-life 2.6 ± 1 h; and mean residence time 2.3 ± 0.64 h.,Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825333/),[l] / [kg·min],0.025,142613,DB01221,Ketamine
,30825333,distribution volume,Pharmacokinetic parameters determined were clearance 0.025 ± 0.008 L/kg/min; distribution volume 3.3 ± 1.3 L/kg; half-life 2.6 ± 1 h; and mean residence time 2.3 ± 0.64 h.,Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825333/),[l] / [kg],3.3,142614,DB01221,Ketamine
,30825333,half-life,Pharmacokinetic parameters determined were clearance 0.025 ± 0.008 L/kg/min; distribution volume 3.3 ± 1.3 L/kg; half-life 2.6 ± 1 h; and mean residence time 2.3 ± 0.64 h.,Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825333/),h,2.6,142615,DB01221,Ketamine
,30825333,mean residence time,Pharmacokinetic parameters determined were clearance 0.025 ± 0.008 L/kg/min; distribution volume 3.3 ± 1.3 L/kg; half-life 2.6 ± 1 h; and mean residence time 2.3 ± 0.64 h.,Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825333/),h,2.3,142616,DB01221,Ketamine
,17083451,plasma concentration,The mean plasma concentration of KET during the 1.5 mg/kg/h KET CRI was 235 ng/mL.,Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[ng] / [ml],235,144216,DB01221,Ketamine
,17083451,elimination half-lives (t1/2alpha,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,2.3,144217,DB01221,Ketamine
,17083451,t1/2beta,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,67.4,144218,DB01221,Ketamine
,17083451,area under the KET,"The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144219,DB01221,Ketamine
,17083451,"plasma concentration-time curve (AUC), elimination","The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144220,DB01221,Ketamine
,17083451,C1,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.24,144221,DB01221,Ketamine
,17083451,C2,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.79,144222,DB01221,Ketamine
,17564643,central volume (V1),"Population parameter estimates and their between subject variability (BSV), standardized to a 70-kg person using allometric models, were central volume (V1) 38.7 (BSV 64%) l.70 kg(-1), peripheral volume of distribution (V2) 102 (51.7%) l.70 kg(-1), clearance (CL) 90 (38.1%) l.h(-1) 70 kg(-1) and intercompartment clearance (Q) 215 (19%) l.h(-1) 70 kg(-1).",Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564643/),[l] / [70·kg],38.7,144751,DB01221,Ketamine
,17564643,peripheral volume of distribution (V2),"Population parameter estimates and their between subject variability (BSV), standardized to a 70-kg person using allometric models, were central volume (V1) 38.7 (BSV 64%) l.70 kg(-1), peripheral volume of distribution (V2) 102 (51.7%) l.70 kg(-1), clearance (CL) 90 (38.1%) l.h(-1) 70 kg(-1) and intercompartment clearance (Q) 215 (19%) l.h(-1) 70 kg(-1).",Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564643/),[l] / [70·kg],102,144752,DB01221,Ketamine
,17564643,clearance (CL),"Population parameter estimates and their between subject variability (BSV), standardized to a 70-kg person using allometric models, were central volume (V1) 38.7 (BSV 64%) l.70 kg(-1), peripheral volume of distribution (V2) 102 (51.7%) l.70 kg(-1), clearance (CL) 90 (38.1%) l.h(-1) 70 kg(-1) and intercompartment clearance (Q) 215 (19%) l.h(-1) 70 kg(-1).",Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564643/),[l] / [70·h·kg],90,144753,DB01221,Ketamine
,17564643,intercompartment clearance (Q),"Population parameter estimates and their between subject variability (BSV), standardized to a 70-kg person using allometric models, were central volume (V1) 38.7 (BSV 64%) l.70 kg(-1), peripheral volume of distribution (V2) 102 (51.7%) l.70 kg(-1), clearance (CL) 90 (38.1%) l.h(-1) 70 kg(-1) and intercompartment clearance (Q) 215 (19%) l.h(-1) 70 kg(-1).",Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564643/),[l] / [70·h·kg],215,144754,DB01221,Ketamine
,29677389,bioavailability,Model-estimated bioavailability of intramuscular ketamine was 41%.,Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29677389/),%,41,146756,DB01221,Ketamine
,20840392,plasma T(max),"Following i.v. administration, plasma T(max) was 0.083 h and plasma C(max) was 18,135 ± 22,720 ng/mL.",Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),h,0.083,146947,DB01221,Ketamine
,20840392,plasma C(max),"Following i.v. administration, plasma T(max) was 0.083 h and plasma C(max) was 18,135 ± 22,720 ng/mL.",Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[ng] / [ml],"18,135",146948,DB01221,Ketamine
,20840392,Plasma AUC,"Plasma AUC was 4484 ± 1,398 ng·h/mL.",Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[h·ng] / [ml],4484,146949,DB01221,Ketamine
,20840392,Plasma t(½β),Plasma t(½β) was 1.80 ± 0.50 h and mean residence time was 0.794 ± 0.318 h with total body clearance of 1.29 ± 0.70 L/h/kg.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),h,1.80,146950,DB01221,Ketamine
,20840392,mean residence time,Plasma t(½β) was 1.80 ± 0.50 h and mean residence time was 0.794 ± 0.318 h with total body clearance of 1.29 ± 0.70 L/h/kg.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),h,0.794,146951,DB01221,Ketamine
,20840392,total body clearance,Plasma t(½β) was 1.80 ± 0.50 h and mean residence time was 0.794 ± 0.318 h with total body clearance of 1.29 ± 0.70 L/h/kg.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[l] / [h·kg],1.29,146952,DB01221,Ketamine
,20840392,plasma steady-state volume of distribution,The mean plasma steady-state volume of distribution was calculated as 0.990 ± 0.530 L/kg and volume of distribution based on area was calculated as 3.23 ± 1.51 L/kg.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[l] / [kg],0.990,146953,DB01221,Ketamine
,20840392,volume of distribution based on area,The mean plasma steady-state volume of distribution was calculated as 0.990 ± 0.530 L/kg and volume of distribution based on area was calculated as 3.23 ± 1.51 L/kg.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[l] / [kg],3.23,146954,DB01221,Ketamine
,20840392,last measurable time,The last measurable time for ketamine detection in plasma was 8.0 h with a mean concentration of 24.9 ± 11.8 ng/mL.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),h,8.0,146955,DB01221,Ketamine
,20840392,T(max),Milk T(max) was detected at 0.67 ± 0.26 h with C(max) of 2495 ± 904 ng/mL.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),h,0.67,146956,DB01221,Ketamine
,20840392,C(max),Milk T(max) was detected at 0.67 ± 0.26 h with C(max) of 2495 ± 904 ng/mL.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[ng] / [ml],2495,146957,DB01221,Ketamine
,20840392,AUC,Milk AUC till the last time was 6593 ± 2617 ng·h/mL with mean AUC milk to AUC plasma ratio of 1.99 ± 2.15.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),[h·ng] / [ml],6593,146958,DB01221,Ketamine
,20840392,AUC milk to AUC plasma ratio,Milk AUC till the last time was 6593 ± 2617 ng·h/mL with mean AUC milk to AUC plasma ratio of 1.99 ± 2.15.,Pharmacokinetics of ketamine in plasma and milk of mature Holstein cows. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840392/),,1.99,146959,DB01221,Ketamine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147638,DB01221,Ketamine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147639,DB01221,Ketamine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147640,DB01221,Ketamine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147641,DB01221,Ketamine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147642,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147643,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147644,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147645,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,168",147646,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147647,DB01221,Ketamine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147648,DB01221,Ketamine
,8735519,infusion rate,"The average mean infusion rate of propofol was 0.136 mg kg-1 min-1, and the ketamine infusion rate was maintained at 50 micrograms kg-1 min-1.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[mg] / [kg·min],0.136,149255,DB01221,Ketamine
,8735519,infusion rate,"The average mean infusion rate of propofol was 0.136 mg kg-1 min-1, and the ketamine infusion rate was maintained at 50 micrograms kg-1 min-1.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[μg] / [kg·min],50,149256,DB01221,Ketamine
,8735519,elimination half-lives,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,69.0,149257,DB01221,Ketamine
,8735519,elimination half-lives,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,89.8,149258,DB01221,Ketamine
,8735519,volumes of distribution at steady state,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[l] / [kg],0.894,149259,DB01221,Ketamine
,8735519,volumes of distribution at steady state,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[l] / [kg],1.432,149260,DB01221,Ketamine
,8735519,body clearances,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[ml] / [kg·min],33.1,149261,DB01221,Ketamine
,8735519,body clearances,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[ml] / [kg·min],23.9,149262,DB01221,Ketamine
,8735519,mean residence times,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,87.1,149263,DB01221,Ketamine
,8735519,mean residence times,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,110.7,149264,DB01221,Ketamine
,8735519,mean residence time,The mean residence time for norketamine was 144 (16) minutes.,Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,144,149265,DB01221,Ketamine
,8735519,times to,"All the ponies recovered quickly from the anaesthesia; the mean times to sternal recumbency and standing were 11.1 (5.3) and 30.0 (20.8) minutes, respectively, from the end of the infusion.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,11.1,149266,DB01221,Ketamine
,8735519,times to,"All the ponies recovered quickly from the anaesthesia; the mean times to sternal recumbency and standing were 11.1 (5.3) and 30.0 (20.8) minutes, respectively, from the end of the infusion.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,30.0,149267,DB01221,Ketamine
,3557733,apparent incorporation constant (ka,The results show a good access capacity of ketamine from the epidural space to the systemic circulation as reflected in the high value of its apparent incorporation constant (ka = 5.54 +/- 2.33 h-1) and its good bioavailability (F = 0.77 +/- 0.22).,Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557733/),1/[h],5.54,156891,DB01221,Ketamine
,3557733,bioavailability (F,The results show a good access capacity of ketamine from the epidural space to the systemic circulation as reflected in the high value of its apparent incorporation constant (ka = 5.54 +/- 2.33 h-1) and its good bioavailability (F = 0.77 +/- 0.22).,Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557733/),,0.77,156892,DB01221,Ketamine
,8634762,flow-rate,The flow-rate was 0.9 ml/min.,Determination of (R)-(+)- and (S)-(-)-isomers of thiopentone in plasma by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634762/),[ml] / [min],0.9,161137,DB01221,Ketamine
,8130056,PaCO2,Halothane was maintained at 1.05-1.07% end-tidal concentration with a PaCO2 of 6-7.3 kPa.,Effect of xylazine and ketamine on the pharmacokinetics of alfentanil during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130056/),kpa,6-7.3,164456,DB01221,Ketamine
,8477017,plasma clearance,Mean plasma clearance of ketamine was 0.94 +/- 0.22 L/kg/h.,Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),[l] / [h·kg],0.94,167769,DB01221,Ketamine
,8477017,elimination half-life,"The elimination half-life was 3.1 +/- 1.6 hours, but in some children late samples indicated an even longer elimination half-life.",Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),h,3.1,167770,DB01221,Ketamine
,8477017,elimination half-life,The elimination half-life of norketamine was estimated to be 6.0 +/- 1.8 hours.,Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),h,6.0,167771,DB01221,Ketamine
,9560536,Pp,"Fifteen minutes after the cessation of propofol infusion, Pp decreased to 1.5 micrograms.","[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),μg,1.5,169344,DB01221,Ketamine
,9560536,Pk,Pk values at 15 minutes and 120 minutes after the cessation of the infusion were 93 ng.,"[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),ng,93,169345,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],0.5,169768,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],1,169769,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],2,169770,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],5,169771,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],8,169772,DB01221,Ketamine
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],11,169773,DB01221,Ketamine
,25212712,volume of distribution in the central,"The volume of distribution in the central and peripheral compartments were 20.5 l∙70 kg(-1) and 220 l∙70 kg(-1), respectively.",Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212712/),[l∙] / [70·kg],20.5,170496,DB01221,Ketamine
,25212712,volume of distribution in the central,"The volume of distribution in the central and peripheral compartments were 20.5 l∙70 kg(-1) and 220 l∙70 kg(-1), respectively.",Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212712/),[l∙] / [70·kg],220,170497,DB01221,Ketamine
,25212712,intercompartmental clearance,"The intercompartmental clearance and total body clearance were 87.3 and 87.9 l·h(-1) ∙70 kg(-1), respectively.",Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212712/),[l·∙] / [70·h·kg],87.3,170498,DB01221,Ketamine
,25212712,total body clearance,"The intercompartmental clearance and total body clearance were 87.3 and 87.9 l·h(-1) ∙70 kg(-1), respectively.",Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212712/),[l·∙] / [70·h·kg],87.9,170499,DB01221,Ketamine
<,20444025,IC(50),"Using a panel of individually expressed canine cytochromes P450 cloned from beagle liver, this report demonstrates that medetomidine is an extremely potent CYP2B11 inhibitor (IC(50) < 10 nm) and that ketamine and midazolam are CYP2B11 substrates with high intrinsic clearances.",Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444025/),nm,10,170559,DB01221,Ketamine
,27044652,anae,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170769,DB01221,Ketamine
,27044652,time,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170770,DB01221,Ketamine
,27044652,time to extubation,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,8.04,170771,DB01221,Ketamine
,6748154,distribution,"In unpremedicated female calves the distribution and elimination half-lives averaged 6.9 and 60.5 min, respectively.",The pharmacokinetics of ketamine administered intravenously in calves and the modifying effect of premedication with xylazine hydrochloride. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748154/),min,6.9,175901,DB01221,Ketamine
,6748154,elimination half-lives,"In unpremedicated female calves the distribution and elimination half-lives averaged 6.9 and 60.5 min, respectively.",The pharmacokinetics of ketamine administered intravenously in calves and the modifying effect of premedication with xylazine hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748154/),min,60.5,175902,DB01221,Ketamine
,6748154,volume of the central compartment,The volume of the central compartment was 1.21 l/kg and the peripheral compartment was 4.04 l/kg.,The pharmacokinetics of ketamine administered intravenously in calves and the modifying effect of premedication with xylazine hydrochloride. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748154/),[l] / [kg],1.21,175903,DB01221,Ketamine
,6748154,peripheral compartment,The volume of the central compartment was 1.21 l/kg and the peripheral compartment was 4.04 l/kg.,The pharmacokinetics of ketamine administered intravenously in calves and the modifying effect of premedication with xylazine hydrochloride. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748154/),[l] / [kg],4.04,175904,DB01221,Ketamine
,6748154,Total body clearance,Total body clearance of ketamine averaged 40.4 ml/min/kg.,The pharmacokinetics of ketamine administered intravenously in calves and the modifying effect of premedication with xylazine hydrochloride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748154/),[ml] / [kg·min],40.4,175905,DB01221,Ketamine
,24049893,Distribution half-life,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,7.4,176035,DB01221,Ketamine
,24049893,elimination half-life,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,259,176036,DB01221,Ketamine
,24049893,volume of the central compartment,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],0.89,176037,DB01221,Ketamine
,24049893,volume of distribution (area),"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],1.98,176038,DB01221,Ketamine
,24049893,volume of distribution at steady state,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],1.9,176039,DB01221,Ketamine
,24049893,total clearance,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[ml] / [kg·min],5.3,176040,DB01221,Ketamine
,24049893,elimination halflife,The 259-minute elimination halflife observed in the present study is consistent with prolonged clinical effectiveness observed in a previous study of antagonism of xylazine/ketamine anesthesia by 4-AP in horses.,Pharmacokinetics of 4-aminopyridine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,259,176041,DB01221,Ketamine
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB01221,Ketamine
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB01221,Ketamine
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB01221,Ketamine
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB01221,Ketamine
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB01221,Ketamine
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB01221,Ketamine
,31827320,clearance,"The clearance of esketamine in two groups was 18.1±3.2 and 18.4±3.4 mL/min•kg, respectively.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),[ml] / [kg·min],18.1,176914,DB01221,Ketamine
,31827320,clearance,"The clearance of esketamine in two groups was 18.1±3.2 and 18.4±3.4 mL/min•kg, respectively.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),[ml] / [kg·min],18.4,176915,DB01221,Ketamine
,31827320,clearance,"However, in the ketamine group, esketamine has a larger clearance than R-ketamine (18.4±3.4 mL/min·kg vs 15.8±3.1 mL/min·kg, P<0.001).","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),[ml] / [kg·min],18.4,176916,DB01221,Ketamine
,31827320,clearance,"However, in the ketamine group, esketamine has a larger clearance than R-ketamine (18.4±3.4 mL/min·kg vs 15.8±3.1 mL/min·kg, P<0.001).","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),[ml] / [kg·min],15.8,176917,DB01221,Ketamine
,31827320,recovery time,"However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),min,9,176918,DB01221,Ketamine
,31827320,recovery time,"However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),min,13,176919,DB01221,Ketamine
,31827320,orientation recovery time,"However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),min,11.5,176920,DB01221,Ketamine
,31827320,orientation recovery time,"However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia.","Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31827320/),min,17,176921,DB01221,Ketamine
over,18396472,recoveries,The recoveries were over 90% in all biological samples tested.,"Analysis of amphetamine-type stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange column-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18396472/),%,90,178357,DB01221,Ketamine
,22774843,pseudo-steady state concentrations,"Blood propofol concentrations during the infusion ranged between 1.52 and 7.65 μg/mL; pseudo-steady state concentrations 3.64-6.78 μg/mL, and concentrations on assuming standing position 0.75-1.40 μg/mL.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[μg] / [ml],3.64-6.78,179623,DB01221,Ketamine
,22774843,clearance,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg·min],31.4,179624,DB01221,Ketamine
,22774843,volume of distribution,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg],220.7,179625,DB01221,Ketamine
,27155360,brain: serum ratio,MXE accumulated in the brain; the brain: serum ratio was between 2.06 and 2.93 throughout the whole observation.,"Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27155360/),,2.06 and 2.93,180339,DB01221,Ketamine
,1466470,Km1,"N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).",Metabolism of ketamine stereoisomers by human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466470/),μM,30-50,181009,DB01221,Ketamine
,1466470,Vmax1,"N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).",Metabolism of ketamine stereoisomers by human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466470/),[nmoles] / [min·nmole],2-6,181010,DB01221,Ketamine
,1466470,Km2,"N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).",Metabolism of ketamine stereoisomers by human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466470/),μM,600-800,181011,DB01221,Ketamine
,1466470,Vmax2,"N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).",Metabolism of ketamine stereoisomers by human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466470/),[nmoles] / [min·nmole],9-15,181012,DB01221,Ketamine
,1770572,time to clear response to verbal commands,The time to clear response to verbal commands after cessation of the continuous infusion was 168 +/- 109 min.,[Continuous infusion of ketamine and midazolam for prolonged sedation in the intensive care unit]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770572/),min,168,183288,DB01221,Ketamine
,1770572,plasma half-life,"The plasma concentrations of ketamine and midazolam decreased rapidly, and plasma half-life of ketamine was about 1 hour and for midazolam less than 2 hours.",[Continuous infusion of ketamine and midazolam for prolonged sedation in the intensive care unit]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770572/),h,1,183289,DB01221,Ketamine
,19807971,time to death,"Retroorbital ketamine-xylazine was the most efficient and consistent of the 3 methods, with an average time to death of approximately 5 s after injection.",Euthanasia method for mice in rapid time-course pulmonary pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19807971/),s,5,186290,DB01221,Ketamine
,28921282,infusion rate,The infusion rate of ketamine was 2 mg·kg-1·hr-1 following a bolus administration of 1.5 mg·kg-1 for the induction of anesthesia.,Pharmacokinetics of ketamine during hypothermic cardiopulmonary bypass in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921282/),[mg] / [h·kg],2,190367,DB01221,Ketamine
,32533977,Ki,"Using radioligand binding assays, U-47700 displayed high affinity for μ-opioid receptors (Ki = 11.1 nM) whereas metabolites were more than 18-fold weaker.","Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533977/),nM,11.1,196033,DB01221,Ketamine
,7431222,(t 1/2)alpha,Ketamine distributed rapidly with (t 1/2)alpha averaging 1.95 min.,Pharmacokinetics of ketamine and two metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),min,1.95,196969,DB01221,Ketamine
,7431222,apparent volumes,"The apparent volumes of the central and peripheral compartments for ketamine averaged 542 and 1940 ml/kg of body weight, respectively, and the (t 1/2)beta averaged 61 min.",Pharmacokinetics of ketamine and two metabolites in the dog. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),[ml] / [kg],542,196970,DB01221,Ketamine
,7431222,apparent volumes,"The apparent volumes of the central and peripheral compartments for ketamine averaged 542 and 1940 ml/kg of body weight, respectively, and the (t 1/2)beta averaged 61 min.",Pharmacokinetics of ketamine and two metabolites in the dog. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),[ml] / [kg],1940,196971,DB01221,Ketamine
,7431222,(t 1/2)beta,"The apparent volumes of the central and peripheral compartments for ketamine averaged 542 and 1940 ml/kg of body weight, respectively, and the (t 1/2)beta averaged 61 min.",Pharmacokinetics of ketamine and two metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),min,61,196972,DB01221,Ketamine
,7431222,apparent volumes of distribution,"The apparent volumes of distribution of I and II averaged 61% and 59% of body weight, respectively.",Pharmacokinetics of ketamine and two metabolites in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),%,61,196973,DB01221,Ketamine
,7431222,apparent volumes of distribution,"The apparent volumes of distribution of I and II averaged 61% and 59% of body weight, respectively.",Pharmacokinetics of ketamine and two metabolites in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),%,59,196974,DB01221,Ketamine
,7431222,total body clearances,"The total body clearances (plasma) of ketamine, I, and II averaged 32.2, 89.4, and 8.54 ml/min/kg, respectively.",Pharmacokinetics of ketamine and two metabolites in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),[ml] / [kg·min],32.2,196975,DB01221,Ketamine
,7431222,total body clearances,"The total body clearances (plasma) of ketamine, I, and II averaged 32.2, 89.4, and 8.54 ml/min/kg, respectively.",Pharmacokinetics of ketamine and two metabolites in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),[ml] / [kg·min],89.4,196976,DB01221,Ketamine
,7431222,total body clearances,"The total body clearances (plasma) of ketamine, I, and II averaged 32.2, 89.4, and 8.54 ml/min/kg, respectively.",Pharmacokinetics of ketamine and two metabolites in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),[ml] / [kg·min],8.54,196977,DB01221,Ketamine
,7431222,Plasma protein binding,"Plasma protein binding was determined by equilibrium dialysis; it averaged 53.5% for ketamine (concentration range 0.34-19.5 micrograms/ml), 60.3% for I (0.05-19.6 micrograms/ml), and 70.1% for II (0.09-0.58 micrograms/ml).",Pharmacokinetics of ketamine and two metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),%,53.5,196978,DB01221,Ketamine
,7431222,Plasma protein binding,"Plasma protein binding was determined by equilibrium dialysis; it averaged 53.5% for ketamine (concentration range 0.34-19.5 micrograms/ml), 60.3% for I (0.05-19.6 micrograms/ml), and 70.1% for II (0.09-0.58 micrograms/ml).",Pharmacokinetics of ketamine and two metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),%,60.3,196979,DB01221,Ketamine
,7431222,Plasma protein binding,"Plasma protein binding was determined by equilibrium dialysis; it averaged 53.5% for ketamine (concentration range 0.34-19.5 micrograms/ml), 60.3% for I (0.05-19.6 micrograms/ml), and 70.1% for II (0.09-0.58 micrograms/ml).",Pharmacokinetics of ketamine and two metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),%,70.1,196980,DB01221,Ketamine
,7431222,minimum anesthetic concentration,A minimum anesthetic concentration of 3 micrograms ketamine HCl/ml plasma was used with the model to predict that the duration of ketamine anesthesia after an i.m. dose would not be significantly affected if the absorption t 1/2 varied from 0.48 to 31 min.,Pharmacokinetics of ketamine and two metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),μg,3,196981,DB01221,Ketamine
,7431222,absorption t 1/2,A minimum anesthetic concentration of 3 micrograms ketamine HCl/ml plasma was used with the model to predict that the duration of ketamine anesthesia after an i.m. dose would not be significantly affected if the absorption t 1/2 varied from 0.48 to 31 min.,Pharmacokinetics of ketamine and two metabolites in the dog. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7431222/),min,0.48 to 31,196982,DB01221,Ketamine
,9736305,Na,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[μM] / [100·g],513,197357,DB01221,Ketamine
,9736305,Na,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[μM] / [100·g],610,197358,DB01221,Ketamine
,9736305,Na,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[ml] / [100·g],1.97,197359,DB01221,Ketamine
,9736305,water excretions,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[μM] / [100·g],610,197360,DB01221,Ketamine
,9736305,water excretions,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[ml] / [100·g],1.97,197361,DB01221,Ketamine
,9736305,water excretions,"Cumulative Na and water excretions were similar (513 and 610 micromol/100 g body weight, 1.97 and 2.35 ml/100 g body weight in SO and UNX, respectively).",Sodium balance and blood pressure response to salt ingestion in uninephrectomized rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736305/),[ml] / [100·g],2.35,197362,DB01221,Ketamine
,10372599,biliary excretion rate,The maximum value for OTC biliary excretion rate (3.69+/-0.6 microg/min/kg) was reached at approximately 17.5 min (time to maximum concentration (tmax)).,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),[μg] / [kg·min],3.69,201553,DB01221,Ketamine
,10372599,time to maximum concentration (tmax),The maximum value for OTC biliary excretion rate (3.69+/-0.6 microg/min/kg) was reached at approximately 17.5 min (time to maximum concentration (tmax)).,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),min,17.5,201554,DB01221,Ketamine
,10372599,biliary excretion (k),"The first-order rate constant for the biliary excretion (k) and the half-life (t1/2) were 6.7x10(-3) min(-1) and 110.55 min, respectively.",Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),1/[min],6.7x10(-3),201555,DB01221,Ketamine
,10372599,half-life (t1/2),"The first-order rate constant for the biliary excretion (k) and the half-life (t1/2) were 6.7x10(-3) min(-1) and 110.55 min, respectively.",Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),min,110.55,201556,DB01221,Ketamine
,10372599,area under the biliary excretion rate time curve (AUC),The mean value of area under the biliary excretion rate time curve (AUC) indicated that 839.77 microg/kg body weight (b.w.) were eliminated by the biliary route.,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),[μg] / [kg],839.77,201557,DB01221,Ketamine
,3589163,t1/2,Plasma ketamine concentrations declined biexponentially with a rapid initial distribution phase (t1/2 2.89 +/- 0.25 minutes) being followed by a slower elimination phase (t1/2 65.84 +/- 3.46 minutes).,Pharmacokinetics of intravenously administered ketamine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589163/),min,2.89,205939,DB01221,Ketamine
,3589163,t1/2,Plasma ketamine concentrations declined biexponentially with a rapid initial distribution phase (t1/2 2.89 +/- 0.25 minutes) being followed by a slower elimination phase (t1/2 65.84 +/- 3.46 minutes).,Pharmacokinetics of intravenously administered ketamine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589163/),min,65.84,205940,DB01221,Ketamine
,17238960,PaCO2,PaCO2 was maintained between 29 and 41 mmHg (3.9-5.5 kPa) and body temperature was kept between 37.8 and 39.3 degrees C.,The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),mmhg,29 and 41,206489,DB01221,Ketamine
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],1.75,206490,DB01221,Ketamine
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],2.69,206491,DB01221,Ketamine
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],5.36,206492,DB01221,Ketamine
,7097501,terminal half-life,Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min.,"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097501/),min,186,209806,DB01221,Ketamine
,7097501,bioavailability,Absorption after intramuscular injection was rapid and the bioavailability was 93%.,"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097501/),%,93,209807,DB01221,Ketamine
,32332467,half-life,Ketamine (K) is used as a party drug with hallucinogenic properties with a half-life of about 2.5 hours.,Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),h,2.5,210256,DB01221,Ketamine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,61,210257,DB01221,Ketamine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,40,210258,DB01221,Ketamine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,96,210259,DB01221,Ketamine
,32332467,K/norketamine,"The K/norketamine and K/dehydronorketamine ratios varied over time between 0.33 and 3.06, and 0.01 and 0.36 for all patients, respectively, implying a large interindividual variation in K metabolism.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),,0,210260,DB01221,Ketamine
,32332467,K/dehydronorketamine,"The K/norketamine and K/dehydronorketamine ratios varied over time between 0.33 and 3.06, and 0.01 and 0.36 for all patients, respectively, implying a large interindividual variation in K metabolism.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),,0,210261,DB01221,Ketamine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],0.5,213228,DB01221,Ketamine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],1.0,213229,DB01221,Ketamine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],2.0,213230,DB01221,Ketamine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],4.0,213231,DB01221,Ketamine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],8.0,213232,DB01221,Ketamine
,19540140,VAS,CRPS pain: Ketamine produced potent analgesia with a significant VAS reduction from 6.2+/-0.2 to 0.4+/-0.3 cm at the end of infusion.,An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540140/),,6.2,214152,DB01221,Ketamine
,19540140,VAS,CRPS pain: Ketamine produced potent analgesia with a significant VAS reduction from 6.2+/-0.2 to 0.4+/-0.3 cm at the end of infusion.,An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540140/),,0.4,214153,DB01221,Ketamine
lower,28550529,brain/plasma ratio,HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration permeated the blood-brain barrier with brain/plasma ratio lower than 1.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),,1,216164,DB01221,Ketamine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,15,216165,DB01221,Ketamine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,54,216166,DB01221,Ketamine
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,95.95,216674,DB01221,Ketamine
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,97.87,216675,DB01221,Ketamine
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,97.70,216676,DB01221,Ketamine
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,98.79,216677,DB01221,Ketamine
,952572,t1/2 (alpha),A rapid distribution phase (t1/2 (alpha) = 3 min) was followed by a slower first-order elimination phase.,Disposition kinetics of ketamine in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952572/),min,3,218310,DB01221,Ketamine
,952572,half-life,The half-life of the drug (66.9 +/- 24.1 min) was independent of the route of parenteral administration.,Disposition kinetics of ketamine in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952572/),min,66.9,218311,DB01221,Ketamine
,952572,Extent of plasma protein binding,"Extent of plasma protein binding, measured in vitro at 5 and 20 mug/ml by equilibrium dialysis technique, was 53 per cent and independent of ketamine concentration.",Disposition kinetics of ketamine in the domestic cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952572/),%,53,218312,DB01221,Ketamine
,952572,Peak tissue level,Peak tissue level of 42 per cent of the dose was reached at 12 to 15 min.,Disposition kinetics of ketamine in the domestic cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952572/),%,42,218313,DB01221,Ketamine
,19733106,peak plasma concentrations,Intranasal (S)-ketamine administration lead to peak plasma concentrations of 27.7+/-5.9ng/ml at 10+/-6.3min (group 1) and 34.3+/-22.2ng/ml at 13.8+/-4.8min after application (group 2).,Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733106/),[ng] / [ml],27.7,219706,DB01221,Ketamine
,19733106,peak plasma concentrations,Intranasal (S)-ketamine administration lead to peak plasma concentrations of 27.7+/-5.9ng/ml at 10+/-6.3min (group 1) and 34.3+/-22.2ng/ml at 13.8+/-4.8min after application (group 2).,Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733106/),[ng] / [ml],34.3,219707,DB01221,Ketamine
,19733106,Maximal plasma concentrations,Maximal plasma concentrations of (S)-norketamine were 18.3+/-14.9ng/ml at 81+/-59min (group 1) and 34.3+/-5.5ng/ml at 75+/-40min (group 2).,Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733106/),[ng] / [ml],18.3,219708,DB01221,Ketamine
,19733106,Maximal plasma concentrations,Maximal plasma concentrations of (S)-norketamine were 18.3+/-14.9ng/ml at 81+/-59min (group 1) and 34.3+/-5.5ng/ml at 75+/-40min (group 2).,Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733106/),[ng] / [ml],34.3,219709,DB01221,Ketamine
,17683400,central volume (V1),"Population parameter estimates for the parent drug, standardized to a 70 kg person using allometric models were central volume (V1) 22 (BSV 89.6%) l.70 kg(-1), peripheral volume of distribution (V2) 129 (30.9%) l.70 kg(-1), clearance other than that metabolized to norketamine (CLother) 47.8 (37.7%) l.h(-1).70 kg(-1) and intercompartment clearance (Q) 216 (54.5%) l.h(-1).70 kg(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·kg],22,221465,DB01221,Ketamine
,17683400,peripheral volume of distribution (V2),"Population parameter estimates for the parent drug, standardized to a 70 kg person using allometric models were central volume (V1) 22 (BSV 89.6%) l.70 kg(-1), peripheral volume of distribution (V2) 129 (30.9%) l.70 kg(-1), clearance other than that metabolized to norketamine (CLother) 47.8 (37.7%) l.h(-1).70 kg(-1) and intercompartment clearance (Q) 216 (54.5%) l.h(-1).70 kg(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·kg],129,221466,DB01221,Ketamine
,17683400,CLother),"Population parameter estimates for the parent drug, standardized to a 70 kg person using allometric models were central volume (V1) 22 (BSV 89.6%) l.70 kg(-1), peripheral volume of distribution (V2) 129 (30.9%) l.70 kg(-1), clearance other than that metabolized to norketamine (CLother) 47.8 (37.7%) l.h(-1).70 kg(-1) and intercompartment clearance (Q) 216 (54.5%) l.h(-1).70 kg(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·h·kg],47.8,221467,DB01221,Ketamine
,17683400,intercompartment clearance (Q),"Population parameter estimates for the parent drug, standardized to a 70 kg person using allometric models were central volume (V1) 22 (BSV 89.6%) l.70 kg(-1), peripheral volume of distribution (V2) 129 (30.9%) l.70 kg(-1), clearance other than that metabolized to norketamine (CLother) 47.8 (37.7%) l.h(-1).70 kg(-1) and intercompartment clearance (Q) 216 (54.5%) l.h(-1).70 kg(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·h·kg],216,221468,DB01221,Ketamine
,17683400,formation clearance (CL2M),"The norketamine formation clearance (CL2M) was 12.4 (127%) l.h(-1).70 kg(-1), elimination clearance (CLM) was 13.5 (145%) l.h(-1).70 kg(-1), and the rate constant for intermediate compartments was 26.5 (59.1%) h(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·h·kg],12.4,221469,DB01221,Ketamine
,17683400,elimination clearance (CLM),"The norketamine formation clearance (CL2M) was 12.4 (127%) l.h(-1).70 kg(-1), elimination clearance (CLM) was 13.5 (145%) l.h(-1).70 kg(-1), and the rate constant for intermediate compartments was 26.5 (59.1%) h(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),[l] / [70·h·kg],13.5,221470,DB01221,Ketamine
,17683400,rate constant,"The norketamine formation clearance (CL2M) was 12.4 (127%) l.h(-1).70 kg(-1), elimination clearance (CLM) was 13.5 (145%) l.h(-1).70 kg(-1), and the rate constant for intermediate compartments was 26.5 (59.1%) h(-1).",Modeling the norketamine metabolite in children and the implications for analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),1/[h],26.5,221471,DB01221,Ketamine
,17683400,elimination half-life,Ketamine has a longer elimination half-life (2.1 h) than norketamine (1.13 h).,Modeling the norketamine metabolite in children and the implications for analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),h,2.1,221472,DB01221,Ketamine
,17683400,elimination half-life,Ketamine has a longer elimination half-life (2.1 h) than norketamine (1.13 h).,Modeling the norketamine metabolite in children and the implications for analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683400/),h,1.13,221473,DB01221,Ketamine
,25702819,plasma clearance,"The median plasma clearance of ketamine after 100 mg 24 h(-1) dose was significantly lower in patients with the CYP2B6*6/*6 (21.6 l h(-1) ) and CYP2B6*1/*6 (40.6 l h(-1) ) genotypes compared with patients with the CYP2B6*1/*1 genotype (68.1 l h(-1) , P < 0.001).",CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25702819/),[l] / [h],21.6,228266,DB01221,Ketamine
,25702819,plasma clearance,"The median plasma clearance of ketamine after 100 mg 24 h(-1) dose was significantly lower in patients with the CYP2B6*6/*6 (21.6 l h(-1) ) and CYP2B6*1/*6 (40.6 l h(-1) ) genotypes compared with patients with the CYP2B6*1/*1 genotype (68.1 l h(-1) , P < 0.001).",CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25702819/),[l] / [h],40.6,228267,DB01221,Ketamine
,25702819,plasma clearance,"The median plasma clearance of ketamine after 100 mg 24 h(-1) dose was significantly lower in patients with the CYP2B6*6/*6 (21.6 l h(-1) ) and CYP2B6*1/*6 (40.6 l h(-1) ) genotypes compared with patients with the CYP2B6*1/*1 genotype (68.1 l h(-1) , P < 0.001).",CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25702819/),[l] / [h],68.1,228268,DB01221,Ketamine
,25702819,plasma clearance,"Patients who experienced adverse effects had lower plasma clearance (45.6 l h(-1) ) than those who did not (52.6 l h(-1) , P = 0.04).",CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25702819/),[l] / [h],45.6,228269,DB01221,Ketamine
,25702819,plasma clearance,"Patients who experienced adverse effects had lower plasma clearance (45.6 l h(-1) ) than those who did not (52.6 l h(-1) , P = 0.04).",CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25702819/),[l] / [h],52.6,228270,DB01221,Ketamine
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,24.6,229514,DB01221,Ketamine
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,35.8,229515,DB01221,Ketamine
,24118506,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mcg] / [l],0.042,229516,DB01221,Ketamine
,24118506,T,Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),,13,229517,DB01221,Ketamine
,24118506,Cmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mg] / [l],0.102,229518,DB01221,Ketamine
,24118506,Tmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),min,8.5,229519,DB01221,Ketamine
,3379668,Systemic availability,Systemic availability was 51% (SEM 10) for the i.m. dose and 43.5% (SEM 6.1) for the rectal dose.,"Pharmacokinetics of ketamine HCl and metabolite I in the cat: a comparison of i.v., i.m., and rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379668/),%,51,231117,DB01221,Ketamine
,3379668,Systemic availability,Systemic availability was 51% (SEM 10) for the i.m. dose and 43.5% (SEM 6.1) for the rectal dose.,"Pharmacokinetics of ketamine HCl and metabolite I in the cat: a comparison of i.v., i.m., and rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379668/),%,43.5,231118,DB01221,Ketamine
,22283551,elimination,"Propofol showed a long elimination half-life (t(1/2λ2) 7.55 ± 9.86 h), whereas ketamine was characterized by shorter half-life (t(1/2λ2) 4 ± 3.4 h) owing to its rapid biotransformation into norketamine.",Pharmacokinetics of ketamine and propofol combination administered as ketofol via continuous infusion in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283551/),h,7.55,232582,DB01221,Ketamine
,22283551,half-life (t(1/2λ2),"Propofol showed a long elimination half-life (t(1/2λ2) 7.55 ± 9.86 h), whereas ketamine was characterized by shorter half-life (t(1/2λ2) 4 ± 3.4 h) owing to its rapid biotransformation into norketamine.",Pharmacokinetics of ketamine and propofol combination administered as ketofol via continuous infusion in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283551/),h,4,232583,DB01221,Ketamine
,2288837,plasma clearance,The mean plasma clearance of morphine was 29 ml min-1 kg-1 and the plasma ratios of morphine-6-glucuronide to morphine were similar to those previously reported in children.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],29,235738,DB01221,Ketamine
,2288837,plasma clearance,The mean plasma clearance of ketamine was 32 ml min-1 kg-1 which is greater than that previously reported in older children and adults.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],32,235739,DB01221,Ketamine
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],355,235889,DB01221,Ketamine
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],1860,235890,DB01221,Ketamine
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],90,235891,DB01221,Ketamine
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],429,235892,DB01221,Ketamine
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],732,235893,DB01221,Ketamine
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],274,235894,DB01221,Ketamine
,16269600,tumor-to-ipsilateral brain ratio,The high boron concentration in brain tumor (76.6 mug/g) and the high tumor-to-ipsilateral brain ratio (6.3) may afford enough radiation doses to destroy the tumor cells while sparing the normal tissues in boron neutron capture therapy.,Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),,6.3,237761,DB01221,Ketamine
,16269600,k(el),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0206,237762,DB01221,Ketamine
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237763,DB01221,Ketamine
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0039,237764,DB01221,Ketamine
,16269600,k(21),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237765,DB01221,Ketamine
,16269600,V(1),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),ml,3.1,237766,DB01221,Ketamine
,25735992,t max,"Plasma JNJ-40411813 exposure was dose-dependent, t max ranged from 3-4 h and t 1/2 19.4-34.2 h across the dose levels.","Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735992/),h,3-4,239446,DB01221,Ketamine
,25735992,t 1/2,"Plasma JNJ-40411813 exposure was dose-dependent, t max ranged from 3-4 h and t 1/2 19.4-34.2 h across the dose levels.","Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735992/),h,19.4-34.2,239447,DB01221,Ketamine
,8522929,T,"Postmortem central blood concentrations were as follows: T = 3 h: 200.8 +/- 129.2 micrograms/mL, T = 6 h: 100.8 +/- 39.6 micrograms/mL and T = 12 h: 480.8 +/- 128.8 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],200.8,241714,DB01221,Ketamine
,8522929,T,"Postmortem central blood concentrations were as follows: T = 3 h: 200.8 +/- 129.2 micrograms/mL, T = 6 h: 100.8 +/- 39.6 micrograms/mL and T = 12 h: 480.8 +/- 128.8 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],480.8,241715,DB01221,Ketamine
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],50.2,241716,DB01221,Ketamine
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),,100.8,241717,DB01221,Ketamine
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],117.7,241718,DB01221,Ketamine
,32724819,m,"The multiple reaction monitoring (MRM) modes of m/z 238.1→m/z 179.1 for KET, m/z 224.1→m/z 207.1 for NK, and m/z 275→m/z 230 for Chlor-Trimeton (IS) were utilized to conduct a quantitative analysis.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),,238.1,242409,DB01221,Ketamine
more,32724819,extraction recoveries,"The extraction recoveries of KET and NK were more than 81.23 ± 3.45% and 80.42 ± 4.57%, respectively.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),%,81.23,242410,DB01221,Ketamine
,32724819,extraction recoveries,"The extraction recoveries of KET and NK were more than 81.23 ± 3.45% and 80.42 ± 4.57%, respectively.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),%,80.42,242411,DB01221,Ketamine
,7459184,T 1/2 alpha,Ketamine was distributed rapidly (T 1/2 alpha = 17 min).,Pharmacokinetics and analgesic effect of ketamine in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7459184/),min,17,244379,DB01221,Ketamine
,7459184,elimination half-life,The elimination half-life was 186 min.,Pharmacokinetics and analgesic effect of ketamine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7459184/),min,186,244380,DB01221,Ketamine
,12538370,total clearance,"The total clearance of ketamine, mean (SD), was 36.0 (13.3) ml min(-1) kg(-1), the volume of distribution (Vbeta) was 16.0 (8.6) litre kg(-1), and the elimination half-life was 4.9 (1.6) h.",Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538370/),[ml] / [kg·min],36.0,245956,DB01221,Ketamine
,12538370,volume of distribution (Vbeta),"The total clearance of ketamine, mean (SD), was 36.0 (13.3) ml min(-1) kg(-1), the volume of distribution (Vbeta) was 16.0 (8.6) litre kg(-1), and the elimination half-life was 4.9 (1.6) h.",Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538370/),[l] / [kg],16.0,245957,DB01221,Ketamine
,12538370,elimination half-life,"The total clearance of ketamine, mean (SD), was 36.0 (13.3) ml min(-1) kg(-1), the volume of distribution (Vbeta) was 16.0 (8.6) litre kg(-1), and the elimination half-life was 4.9 (1.6) h.",Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538370/),h,4.9,245958,DB01221,Ketamine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,4.1,247369,DB01221,Ketamine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,0.98,247370,DB01221,Ketamine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,1.55,247371,DB01221,Ketamine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],41,247372,DB01221,Ketamine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"14,494",247373,DB01221,Ketamine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"7,426",247374,DB01221,Ketamine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],6.3,247375,DB01221,Ketamine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],616.7,247376,DB01221,Ketamine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],328,247377,DB01221,Ketamine
,2013837,KET,kg-1.min-1 for 5 hr accompanied by an initial loading dose (26 mg/kg administered over 20 min) designed to produce a stable KET of 20 micrograms/ml of plasma.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),[μg] / [ml],20,250399,DB01221,Ketamine
,2013837,t1/2 beta,Group 2: t1/2 beta = 122 +/- 9 vs.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),,122,250400,DB01221,Ketamine
,2013837,CL,141 +/- 40 min (mean +/- SD) and CL = 18.1 +/- 5.9 vs.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),,18.1,250401,DB01221,Ketamine
,2013837,KET,"When administered as a continuous infusion (Group 2), KET remained relatively stable at 22.1 +/- 4.6 micrograms/ml for 5 hr.",The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),[μg] / [ml],22.1,250402,DB01221,Ketamine
,2253657,steady-state levels,"In 9 of the patients who had normal liver and kidney function (group 1), steady-state levels after 3 days of continuous infusion were 1.2 +/- 0.3 micrograms/ml ketamine, 1.0 +/- 0.6 micrograms/ml norketamine, and 2.6 +/- 1.0 micrograms/ml dehydronorketamine.","Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253657/),[μg] / [ml],1.2,251070,DB01221,Ketamine
,2253657,steady-state levels,"In 9 of the patients who had normal liver and kidney function (group 1), steady-state levels after 3 days of continuous infusion were 1.2 +/- 0.3 micrograms/ml ketamine, 1.0 +/- 0.6 micrograms/ml norketamine, and 2.6 +/- 1.0 micrograms/ml dehydronorketamine.","Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253657/),[μg] / [ml],1.0,251071,DB01221,Ketamine
,2253657,steady-state levels,"In 9 of the patients who had normal liver and kidney function (group 1), steady-state levels after 3 days of continuous infusion were 1.2 +/- 0.3 micrograms/ml ketamine, 1.0 +/- 0.6 micrograms/ml norketamine, and 2.6 +/- 1.0 micrograms/ml dehydronorketamine.","Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253657/),[μg] / [ml],2.6,251072,DB01221,Ketamine
,7198883,Plasma levels,"Plasma levels of ketamine varied from 9,000 to 25,800 ng/ml 1 minute after injection to approximately 1,000 ng/ml when the patients began to recover consciousness.",Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198883/),[ng] / [ml],"9,000 to 25,800",251209,DB01221,Ketamine
,7198883,Plasma levels,"Plasma levels of ketamine varied from 9,000 to 25,800 ng/ml 1 minute after injection to approximately 1,000 ng/ml when the patients began to recover consciousness.",Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198883/),[ng] / [ml],"1,000",251210,DB01221,Ketamine
,7198883,peak,Ketamine metabolite II levels were lower with a peak of 515 ng/ml in approximately 60 minutes to 13 to 27 ng/ml 24 hours later.,Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198883/),[ng] / [ml],515,251211,DB01221,Ketamine
,7198883,peak,Ketamine metabolite II levels were lower with a peak of 515 ng/ml in approximately 60 minutes to 13 to 27 ng/ml 24 hours later.,Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198883/),[ng] / [ml],13 to 27,251212,DB01221,Ketamine
,30938060,length to detector,The separation is performed in a 15 μm capillary with an overall length of 31.5 cm and length to detector of 18 cm; inner surface of the capillary is covered with a commercial coating solution to reduce the electroosmotic flow.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),cm,18,256595,DB01221,Ketamine
,30938060,migration time,"In an optimised background electrolyte with composition 2 M acetic acid + 1% v/v coating solution under application of a high voltage of 30 kV, the migration time is 97.1 s for ketamine and 95.8 s for norketamine, with an electrophoretic resolution of 1.2.",Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),s,97.1,256596,DB01221,Ketamine
,30938060,migration time,"In an optimised background electrolyte with composition 2 M acetic acid + 1% v/v coating solution under application of a high voltage of 30 kV, the migration time is 97.1 s for ketamine and 95.8 s for norketamine, with an electrophoretic resolution of 1.2.",Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),s,95.8,256597,DB01221,Ketamine
,30938060,detection limit,The attained detection limit was 83 ng/mL (0.3 μmol/L) for ketamine and 75 ng/mL (0.3 μmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 μg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),[ng] / [ml],83,256598,DB01221,Ketamine
,30938060,detection limit,The attained detection limit was 83 ng/mL (0.3 μmol/L) for ketamine and 75 ng/mL (0.3 μmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 μg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),[μM] / [l],0.3,256599,DB01221,Ketamine
,30938060,detection limit,The attained detection limit was 83 ng/mL (0.3 μmol/L) for ketamine and 75 ng/mL (0.3 μmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 μg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),[ng] / [ml],75,256600,DB01221,Ketamine
,30938060,detection limit,The attained detection limit was 83 ng/mL (0.3 μmol/L) for ketamine and 75 ng/mL (0.3 μmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 μg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),[μM] / [l],0.3,256601,DB01221,Ketamine
,30938060,detection limit,The attained detection limit was 83 ng/mL (0.3 μmol/L) for ketamine and 75 ng/mL (0.3 μmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 μg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine.,Rapid electrophoretic monitoring of the anaesthetic ketamine and its metabolite norketamine in rat blood using a contactless conductivity detector to study the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30938060/),[plates] / [m],695 400,256602,DB01221,Ketamine
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.020,260954,DB01221,Ketamine
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.024,260955,DB01221,Ketamine
,29771709,Total pharmacokinetic flow,"Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(-) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),[l] / [min],7.59,265177,DB01221,Ketamine
,29771709,S(+,"Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(-) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),[l] / [min],1.23,265178,DB01221,Ketamine
,29771709,R(-),"Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(-) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),[l] / [min],1.23,265179,DB01221,Ketamine
,29771709,elimination clearances,"Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(-) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),[l] / [min],1.23,265180,DB01221,Ketamine
,29771709,elimination clearances,"Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(-) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),[l] / [min],1.06,265181,DB01221,Ketamine
,29771709,link rate constant,"The arm-tissue link rate constant was 0.18 ± 0.01 min, and the fraction of arm blood flow estimated to exchange with arm tissue was 0.04 ± 0.01.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),min,0.18,265182,DB01221,Ketamine
,29771709,fraction of arm blood flow,"The arm-tissue link rate constant was 0.18 ± 0.01 min, and the fraction of arm blood flow estimated to exchange with arm tissue was 0.04 ± 0.01.",Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(-) Ketamine Concentrations. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771709/),,0.04,265183,DB01221,Ketamine
,29126076,analytical run time,"The method involves the deproteinization of a small amount of biological matrix (corresponding to 5μL of plasma, 10mg of brain, or 2.5μL of CSF) using a water-miscible organic solvent containing 2H4-norketamine as an internal standard, the direct injection of the organic supernatant into an LC-MS/MS system, chiral separation on a CHIRALPAK AS-3R column (4.6mm i.d.×100mm, 3μm particles), and detection by electrospray ionization-selected reaction monitoring with an analytical run time of 5min.","A rapid and sensitive chiral LC-MS/MS method for the determination of ketamine and norketamine in mouse plasma, brain and cerebrospinal fluid applicable to the stereoselective pharmacokinetic study of ketamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29126076/),min,5,266002,DB01221,Ketamine
,34265182,steady-state concentrations,"The estimated model parameters were used to simulate serum concentration-time profiles; after multiple dosing of PR-ketamine (2 daily doses of 20 mg), the steady-state concentrations of R- and S-ketamine were 1.4 and 1.3 ng/mL, respectively.","Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265182/),[ng] / [ml],1.4,267633,DB01221,Ketamine
,34265182,steady-state concentrations,"The estimated model parameters were used to simulate serum concentration-time profiles; after multiple dosing of PR-ketamine (2 daily doses of 20 mg), the steady-state concentrations of R- and S-ketamine were 1.4 and 1.3 ng/mL, respectively.","Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265182/),[ng] / [ml],1.3,267634,DB01221,Ketamine
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],29.9,270156,DB01221,Ketamine
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],22.2,270157,DB01221,Ketamine
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.31,270158,DB01221,Ketamine
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.16,270159,DB01221,Ketamine
,10598617,total volume of distribution,The peripheral tissue distribution volumes and clearances and the total volume of distribution (2.1 l/kg) were the same for both stereoisomers when elimination clearances were modeled from the rapidly equilibrating peripheral compartment.,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[l] / [kg],2.1,270160,DB01221,Ketamine
,20305886,plasma concentration,"A pharmacokinetic study provided dexmedetomidine plasma concentration, set to be 3.0 ng*mL(-1).",Hemodynamics and bispectral index (BIS) of dogs anesthetized with midazolam and ketamine associated with medetomidine or dexmedetomidine and submitted to ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305886/),[ng] / [ml],3.0,270806,DB01221,Ketamine
,32222343,volume of distribution at steady state (Vss),"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],3217,271010,DB01221,Ketamine
,32222343,metabolic clearance,"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],88,271011,DB01221,Ketamine
,32222343,terminal half-life,"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,59,271012,DB01221,Ketamine
,32222343,Vss,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],3224,271013,DB01221,Ketamine
,32222343,Vss,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],2073,271014,DB01221,Ketamine
,32222343,total metabolic clearance,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],107,271015,DB01221,Ketamine
,32222343,total metabolic clearance,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],52,271016,DB01221,Ketamine
,32222343,terminal half-lives,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,52,271017,DB01221,Ketamine
,32222343,terminal half-lives,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,55,271018,DB01221,Ketamine
,31798415,S-slope,"In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively.",Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31798415/),1/[μM],0.23,271213,DB01221,Ketamine
,31798415,S-slope,"In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively.",Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31798415/),1/[μM],1.9,271214,DB01221,Ketamine
,1155748,serum half-life,"The serum half-life of ketamine was in alpha-phase about 11 min, the predominant half-life for the beta-phase 2.5 h.",Pharmacokinetics of ketamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1155748/),min,11,272833,DB01221,Ketamine
,1155748,half-life,"The serum half-life of ketamine was in alpha-phase about 11 min, the predominant half-life for the beta-phase 2.5 h.",Pharmacokinetics of ketamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1155748/),h,2.5,272834,DB01221,Ketamine
